
==== Front
J Neuroinflammation
J Neuroinflammation
Journal of Neuroinflammation
1742-2094
BioMed Central London

39285276
3222
10.1186/s12974-024-03222-4
Review
Microenvironmental regulation of tumor-associated neutrophils in malignant glioma: from mechanism to therapy
Wen Jiayi 1
Liu Dan 2
Zhu Hongtao zhuhongtao@tjh.tjmu.edu.cn

1
Shu Kai kshu@tjh.tjmu.edu.cn

1
1 grid.33199.31 0000 0004 0368 7223 Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030 China
2 grid.33199.31 0000 0004 0368 7223 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
16 9 2024
16 9 2024
2024
21 22617 5 2024
3 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Glioma is the most common primary intracranial tumor in adults, with high incidence, recurrence, and mortality rates. Tumor-associated neutrophils (TANs) are essential components of the tumor microenvironment (TME) in glioma and play a crucial role in glioma cell proliferation, invasion and proneural-mesenchymal transition. Besides the interactions between TANs and tumor cells, the multi-dimensional crosstalk between TANs and other components within TME have been reported to participate in glioma progression. More importantly, several therapies targeting TANs have been developed and relevant preclinical and clinical studies have been conducted in cancer therapy. In this review, we introduce the origin of TANs and the functions of TANs in malignant behaviors of glioma, highlighting the microenvironmental regulation of TANs. Moreover, we focus on summarizing the TANs-targeted methods in cancer therapy, aiming to provide insights into the mechanisms and therapeutic opportunities of TANs in the malignant glioma microenvironment.

Keywords

Malignant glioma
Tumor-associated neutrophils
Tumor microenvironment
Immunotherapy
Targeted therapy
http://dx.doi.org/10.13039/501100002858 China Postdoctoral Science Foundation 2022M711253 http://dx.doi.org/10.13039/501100003819 Natural Science Foundation of Hubei Province 2023AFB135 the postdoctoral innovation research position funding of Hubei province (2022)http://dx.doi.org/10.13039/501100012166 National Key Research and Development Program of China 2023YFC2510000 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Glioma is the most common primary intracranial tumor in adults, with high incidence, recurrence, and mortality rates [1]. Overall, the broad category of gliomas (ICD-O-3 histology codes 9380–9384 and 9391–9460) represents approximately 24.5% of all primary brain tumors and 80.9% of all malignant tumors in adults [2]. Glioblastoma (GB), classified as grade 4, adult-type diffuse gliomas, represents the most common malignant brain tumor in adults with a 5-year survival rate of only 6.8% [2–4]. Current treatments for newly diagnosed patients suggested by newest guidelines mainly involve maximum safe surgical resection, followed by radiotherapy (RT) and radiochemotherapy combined with temozolomide (TMZ), as well as other combination treatments such as adjuvant chemotherapy and Tumor Treating Fields [4, 5]. Over the past decade, treatment strategies for glioma have continued to evolve. However, due to the highly invasive and drug resistance of glioma, the overall survival (OS) of glioma patients has not significantly improved, novel therapeutic targets and precision treatment strategies are urgently needed [6].

The tumor microenvironment (TME) is a key factor in tumor progression and has been one of the research hotspots in recent years. It is generally believed that the TME plays a crucial role in various malignant behaviors such as proliferation, invasion, angiogenesis, and drug resistance. In glioma TME, non-tumor cells mainly include tumor-associated macrophages (TAMs), dendritic cells (DCs), tumor-associated neutrophils (TANs), lymphocyte, astrocyte, endothelial cells, and others [7]. Previous studies focused more on the role of TAMs and other cells in the glioma microenvironment, the function of TANs was not appreciated for a long time because it was not as abundant as TAMs. With the development of bioinformatic analysis tools and single-cell transcriptome sequencing technology in recent years, the role of TANs in the progression of various tumors, including glioma, has been gradually discovered and attracted attention [8, 9].

Neutrophils are the most abundant myeloid cells in the circulation of humans and mice, with a ratio to monocytes of approximately 7:1 to 10:1 [10]. During the pathophysiological process of tumors, neutrophils proliferate, extravasate, and enter the TME from the peripheral blood through specific mechanisms, becoming TANs. Studies over the past decade have shown that TANs are not merely inert “bystanders” as traditionally believed, but rather important components that influence tumor progression and exhibit both pro-tumor and anti-tumor effects [11–16]. Histologically, it has been confirmed that neutrophils infiltrate more in malignant glioma [17]. Substances produced by TANs, such as matrix metalloproteinase 9 (MMP9), promote angiogenesis in glioma [18]. Furthermore, the role of TANs in resisting anti-angiogenic therapy and immune checkpoint therapy has been confirmed [19]. Conversely, other studies have shown that TANs also play an anti-tumor role, such as direct or indirect cytotoxic effects [20, 21]. The functions of TANs in glioma microenvironment are context-dependent and still need deep investigation.

In this review, we mainly discuss how TANs participate in the malignant behavior of glioma, including the origin of TANs, the impacts of TANs on glioma cells, and a particular focus on the microenvironmental regulation of TANs. We also summarize the research progress of TANs-targeted therapies in glioma treatment and novel neutrophil-based drug delivery systems in cancer therapy, with an attempt to highlight the important roles of TANs in glioma microenvironments and tumor progression, which finally shed light on TANs-targeted glioma therapy.

From neutrophils to tumor-associated neutrophils

Neutrophils develop and mature in the bone marrow

Neutrophils, recognized as crucial participants in acute inflammation, are a subset of polymorphonuclear leukocytes. They are typically the first leukocytes to be recruited to inflammatory sites, including tumors, exerting a significant impact on tumor progression [11, 22]. Neutrophils continuously originate from myeloid stem cells in the bone marrow. Granulocyte colony-stimulating factor (G-CSF) plays a pivotal role in promoting this process. During maturation, neutrophils go through the following stages: myeloblast, promyelocyte, myelocyte, metamyelocyte, band granulocyte, and eventually become mature polymorphonuclear/segmented granulocyte [22]. Mature neutrophils express G-CSF receptor (G-CSF-R), Toll-like receptors (TLRs), and CXC chemokine receptor 2 (CXCR2) on their surfaces. These receptors are closely associated with the egress of neutrophils from the bone marrow [22] (Fig. 1).

Fig. 1 Neutrophil maturation and recruitment Neutrophils develop and mature in the bone marrow. Mature neutrophils travel out of the bone marrow into the peripheral blood in the presence of G-CSF, GM-CSF, TLR ligands and CXCLs. Subsequently, cytokines such as CXCLs, IL-1β and other cytokines recruit neutrophils into the TME. Neutrophils enter the TME and become TANs and differentiate into N1 and N2 types in response to IFN-γ, TGF-β signaling. New TANs classifications identified by dcTRAIL-R1 and CD101 statuses

Neutrophils are recruited to the TME and designated as TANs

In patients with solid tumors, mature neutrophils in the organism are classified into two major categories based on their localization—peripheral blood neutrophils (PBNs) and TANs infiltrating the tumor tissue [14]. The neutrophil-to-lymphocyte ratio (NLR), the ratio of neutrophil count to lymphocyte count in peripheral blood, is a biomarker linking the neutrophil-dominated innate immune response to the lymphocyte-supported adaptive immunity [23]. NLR can to some extent reflect the status of TME, serving as a commonly used indicator for clinical efficacy assessment and prognosis evaluation [24]. For example, patients with high NLR values are diagnosed with high-grade glioma and associated with poor OS [24].

Under the influence of several molecules (see below), neutrophils move out from the blood and are recruited into the TME. When neutrophils traffic into TME, they are referred to as TANs [14]. Studies indicate that CXCR2 is a critical molecular mediator of neutrophil recruitment. CXCR2, expressed on the surface of neutrophils, is functionally associated with mediating neutrophil activation [25, 26]. The level of CXCR2 is closely correlated with the prognosis of glioma. Yang et al. have demonstrated that elevated CXCR2 levels indicate a significantly higher recurrence and metastasis rate in glioma patients, serving as an adverse prognostic indicator [27]. Glioma cells produce G-CSF and granulocyte-macrophage colony-stimulating factor (GM-CSF), promoting the egress of neutrophils from the bone marrow and prolonging their lifespan [16, 28, 29]. This process is also closely associated with CXCR2 and its ligands CXC motif ligands (CXCLs) [29]. CXCR2 ligands include CXCL1, CXCL2, CXCL5, CXCL6, CXCL8 (Interleukin-8, IL-8), with IL-8 playing a crucial role in the recruitment of neutrophils to the microenvironment of glioma. Various components in the TME, such as IL-1β, TNF-α, can stimulate GB cells to produce IL-8, recruiting neutrophils (Fig. 2A) [30–32]. Fas in the TME, when bound to FasL on the surface of glioma cells, activates downstream signaling pathways, promoting the expression of IL-8 and recruiting neutrophils (Fig. 2B) [33]. Additionally, neutrophil extracellular traps (NETs) can promote the secretion of IL-8 by glioma cells through the HMGB1/RAGE/NF-κB axis, recruiting neutrophils [34]. These neutrophils, in turn, mediate the formation of NETs through the PI3K/AKT/ROS axis, creating a positive feedback loop (Fig. 2C) [34]. It has also been found that IL-8/CXCL1 interaction likewise plays an important role in TANs recruitment in the zebrafish glioma model [35]. Apart from IL-8, IL-1β is also an essential cytokine for promoting neutrophil recruitment. Wang et al. have suggested that the binding of LINC01116 to DDX5 promotes the expression of IL-1β in glioma cells, facilitating the recruitment of neutrophils (Fig. 2D) [36]. Lee et al. have indicated that ectopic expression of CD133 induces an increase in IL-1β expression, which promotes neutrophil recruitment (Fig. 2E) [37].

Fig. 2 Recruitment of TANs IL-8 and IL-1β can recruit neutrophils into TME. (A) IL-1β, TNF-α in TME improve IL-8 production in glioma cells. (B) FasL in TME improves IL-8 production in glioma cells. (C) Positive feedback loop in TANs and glioma cells. NETs produce HMGB1 and promote IL-8 secretion in glioma cells by HMGB1/RAGE/NF-κB axis. IL-8 binds to CXCR2 on TANs promoting NETs formation by PI3K/AKT/ROS axis. (D) LINC01116 combined with DDX5 promote IL-1β secretion in glioma cells. (E) Ectopic expression of CD133 in glioma stem cells stimulates glioma cells secreting IL-1β

TANs are “educated” to play dual roles in TME

Numerous studies indicate that TANs exhibit both pro- and anti-tumor effects. In a considerable portion of research, like the differentiation of TAMs into M1-like and M2-like phenotypes, TANs are also described as N1-type (with anti-tumor effects) and N2-type (with pro-tumor effects) [11, 38, 39]. Several molecules have been identified to distinguish between N1 and N2. N1 markers include intercellular cell adhesion molecule-1 (ICAM-1), inducible nitric oxide synthase (iNOS), C-C motif ligand 3 (CCL3), tumor necrosis factor-α (TNF-α), etc.; N2 markers include CCL17, CCL2, arginine (Arg), CCL5, vascular endothelial growth factor (VEGF), etc [35]. What is clearer is that transforming growth factor-β (TGF-β) signaling in the TME tends to drive neutrophils towards a pro-tumor phenotype (N2), while type I interferon (IFN) signaling or inhibition of TGF-β signaling can drive neutrophils towards an anti-tumor phenotype (N1) [38]. In addition, N1 and N2-type TANs may also vary with TME: in early tumor stages, TANs exhibit stronger cytotoxic effects on tumor cells, whereas in advanced tumor stages, TANs exhibit more of a pro-tumor phenotype [40, 41]. (Fig. 1)

Some scRNAseq data suggest that N1/N2 may not be the so-called ‘polarization’ in different directions, but rather that TANs exhibit different effects on tumor cells at different degrees of activation. Using scRNAseq technology, they identified TANs as different from N1/N2 in multiple differentiation states. Wu and colleagues identified TANs as 10 distinct transcriptional states, including inflammation, angiogenesis, and antigen presentation, from 225 samples from 17 cancer types [8]. A newly published article in Science presents a novel perspective on TANs recruitment and reprogramming [42]. In pancreatic tumor model, researchers classified infiltrating neutrophils into three different neutrophil states, T1, T2 and T3 [42]. Their states can be determined by dcTRAIL-R1 and CD101, i.e., T1 (dcTRAIL-R1−CD101−), T2 (dcTRAIL-R1−CD101+), and T3 (dcTRAIL-R1+) [42]. Of these, T1 and T2 neutrophils are transitional neutrophil populations, differentiated from immature and mature neutrophils, respectively, while T3 neutrophils are in a terminally differentiated state, formed by further reprogramming of T1 and T2 neutrophils [42]. This process is irreversible [42]. In addition, the researchers further found that TME stimuli are necessary for the upregulation of dcTRAIL-R1 i.e., the shift to T3 neutrophils, but this process does not require the intervention of any tumor-soluble factors [42]. This finding suggests a defined program within neutrophils that enables them to acquire the T3 phenotype independent of their maturation stage [42]. At the functional level, T3 neutrophils are located in hypoxic niche and highly express VEGFA, promoting angiogenesis and tumor growth [42]. (Fig. 1)

TANs involving in malignant behaviors of tumor

TANs promote tumor invasion

Several studies across different tumors have confirmed the correlation of TANs with the invasiveness, malignancy, and adverse prognosis of tumors, and that neutrophil depletion therapy contributes to promoting survival [43]. The invasion of tumor cells into normal brain tissue is a characteristic of malignant glioma [44]. Isocitrate dehydrogenase (IDH), a key enzyme in the Krebs cycle, catalyzes the oxidative decarboxylation of isocitrate. IDH has two isoforms, IDH1 and IDH2, with most mutations involving the substitution of arginine at position 132 by histidine in IDH1 (R132H) and arginine at position 172 by lysine in IDH2 (R172K) [45]. Based on the status of IDH, glioma can be classified into wild-type IDH (wt-IDH) and mutant IDH (mu-IDH) [45]. Compared with wt-IDH, mu-IDH exhibits weaker invasiveness and higher rates of progression-free survival (PFS) [45, 46]. Amankulor et al. compared the immune cell composition in wt-IDH1 and mu-IDH1 glioma and found that mu-IDH1 glioma had fewer immune cell infiltration, especially neutrophils [17]. Also, they noted a lower presence of neutrophil chemokines in the homogenates of mu-IDH1 glioma [17]. Further, neutrophil depletion using an anti-Ly6g antibody had a significant survival benefit in wt-IDH1 glioma mice and no significant effect in mu-IDH1 glioma mice [17, 47].

The awakening of dormant tumor cells is a common cause of tumor invasion, metastasis, and recurrence. In experimental tumor models, NETs formed during the inflammation can awaken tumor cells [48]. NETs, generated by neutrophils, are extracellular network structures constructed from DNA fiber (nuclear and/or mitochondrial DNA) and modified with histones and enzymes [48, 49]. Neutrophil elastase (NE) and MMP9 are pivotal among these. Using a model of lung cancer caused by chronic inflammation, Albrengues et al. have found that NETs DNA connects to the extracellular matrix (ECM), transports NE and MMP9 released by neutrophils to the vicinity of the substrate, facilitating the breakdown and reorganization of laminin [50]. This recombined laminin awakens dormant cancer cells via integrin activation and the FAK/ERK/MLCK/YAP signaling pathway, promoting aggressive tumor growth and metastasis [50]. Studies on various intracranial tumors similarly support the promoting role of these two enzymes in tumor invasion. NE is absent in normal brain tissue but is present in the border zones of high-grade glioma [51, 52]. Compared to low-grade glioma, the borders of GB exhibit more NE, correlating with stronger invasiveness [51]. A study including samples from 62 glioma patients (surgical or biopsy) has suggested that higher levels of MMP9 in glioma mean stronger invasiveness, higher grades, and poorer prognosis [53]. Additionally, MMP9 promotes the proliferation of glioma cells [53]. (Fig. 3A)

TANs promote tumor proliferation

TANs have been shown to directly promote tumor cell proliferation. Researchers co-cultured U87MG glioma cells with human neutrophils and observed neutrophil promotion of glioma cell proliferation in both 2D and 3D co-culture experiments [54]. Interestingly, soluble factors mediating glioma-neutrophil communication vary over time. After 24 h and 72 h of co-cultivation, the production of IL-8 in glioma-neutrophil cultures increased significantly and decreased sharply after 120 h. The production pattern of TNF-α is similar to IL-8. The opposite was observed for IL-1β. It was virtually unproduced in the first few hours, but its release rose after 120 h [54]. Correspondingly, glioma cells were attacked by neutrophils in the first 24 h of co-cultivation, and after 120 h, tumors responded to the presence of neutrophils with increased viability [54]. The crosstalk between neutrophils and glioma cells potentiates the differential release of immune cell recruiting and suppression molecules promoting tumor progression [54]. One study based on zebrafish glioblastoma model indicated that neutrophils are recruited in early stage during oncogenesis and increases tumor cell proliferation [35]. The possible explanation is that ROS released by TANs can cause DNA damage and induce tumorigenesis in peri-tumor cells [35, 54]. Both lung adenocarcinoma model and non-small cell lung cancer (NSCLC) model confirm that TANs produce NE, which promotes tumor cell proliferation by upregulating the PDGFR/PI3K pathway and PGE2 synthesis [55, 56]. CCK8 assay demonstrated that NETs significantly contributed to the proliferation rate of glioma cells, which was reduced by DNase I, hydrolase can degrade NETs [34]. Although NE is an important component of NETs, it is not clear whether the role of NETs in promoting tumor proliferation is wholly or partially dependent on NE. TANs also promote tumor proliferation indirectly through the secretion of soluble factors. Bone morphogenetic protein 2 (BMP2) and TGF-β2 secreted by TANs promote the expression of miR-301b-3p in hepatocellular carcinoma (HCC), which has been shown to promote hepatocellular carcinoma (HCC) proliferation and stem cell characteristics [57]. Meanwhile, miR-301b-3p can suppress CYLD expression in HCC cells, consequently leads to hyperactive NF-κB signaling, higher level of CXCL5 secretion, and more TANs recruitment, forming a positive feedback loop [57]. (Fig. 3B)

Many studies focus on the role of ferroptosis of tumor cells on tumor invasion and proliferation, but contradictions still exist. TANs are closely associated with ferroptosis of tumor cells. TANs transfer myeloperoxidase (MPO)-containing particles into GB cells, and MPO mediates ferroptosis of GB cells by increasing lipid-based ROS, clarifying the mechanism of necrosis in GB cells [58]. In triple-negative breast cancer (TNBC), TANs produce NETs, which mediate ferroptosis resistance of TNBC cells through the TLR9/Merlin signaling axis and promote TNBC proliferation [59]. Both TANs-mediated ferroptosis resistance and ferroptosis of tumor cells enhance the invasiveness of tumor and suggest a poor prognosis [58, 59]. (Fig. 3B)

TANs promote tumor angiogenesis

Like normal organs, tumor tissues obtain oxygen and nutrients through blood vessels, which is mainly achieved through angiogenesis. As a critical manifestation of glioma progression, angiogenesis mainly involves the following steps: (1) vascular rupture, (2) degradation of the vascular basement membrane and surrounding extracellular matrix (ECM), and (3) migration of vascular endothelial cells (ECs) and new blood vessel formation [60]. TANs predominantly influence steps (2) and (3). Various evidence indicates that neutrophils play a significant role in angiogenesis under normal physiological conditions [61]. In the context of cancer, TANs serve as a significant source of pro-angiogenic factors in the TME, no less than TAMs [18]. TANs promote tumor angiogenesis mainly through interaction with ECs.

VEGF/VEGFR interactions, one of the most classical pathways in ECs, activate downstream pathways including PLC/ERK pathway, PI3K/AKT/mTOR pathway, small GTPases, and others [62]. They are widely involved in vascular development, cell survival, regulation of vasomotion, cell shape, cell migration and polarization, and many other processes [62]. TANs can produce large amounts of VEGFA, which stimulates ECs and promotes tumor angiogenesis through the VEGFA/VEGFR2 pathway [18]. In addition, since a large amount of VEGF is sequestered in the ECM in an inactivated form, MMP9, produced by TANs, degrades ECM and releases a large amount of VEGF, which effects on the nearby ECs and promotes tumor angiogenesis [18, 61]. The activity of MMP9 is inhibited by tissue inhibitors of metalloproteinase-1 (TIMP-1). This inhibitor is often released in conjunction of MMP9 to form an MMP9/TIMP-1 complex thereby preventing its protein hydrolysis activity [61]. However, TANs do not express tissue inhibitors of metalloproteinase-1 (TIMP-1), which forms an MMP-9/TIMP-1 complex with MMP9 to inhibit its protein hydrolysis activity, thus requiring only a small amount of TANs to produce significant pro-tumor angiogenic effects [61, 63]. In addition, IL-8 secreted by tumor cells recruits TANs and facilitates the rapid release of MMP9 from TANs. Meanwhile, MMP9 can potentiate IL-8 via amino-terminal processing, resulting in a 10-fold higher potency in TANs activation, consequently promoting MMP9 release and IL-8 mediated recruitment of TANs. This creates a positive feedback loop, recruiting more TANs and promoting more angiogenesis [61, 64–66]. (Fig. 3C)

Bv8 (also known as prokineticin 2) is important in promoting tumor angiogenesis [67]. As a homolog of endocrine gland-derived VEGF (EG-VEGF), Bv8 plays the role of mitogen or survival factor of ECs in angiogenesis [68]. Studies have shown that G-CSF activates the JAK signaling and STAT3 pathways, promoting neutrophil proliferation [18]. Meanwhile, G-CSF induces the upregulation of Bv8 expression on neutrophils in a STAT3-dependent manner [69, 70]. Bv8 can activate STAT3 in a JAK2-dependent manner, establishing a positive feedback loop that generates a large amount of Bv8 in the TME and promotes tumor angiogenesis [69, 70]. Blocking Bv8, in turn, can inhibit glioma angiogenesis [71]. Unlike VEGFR (a kind of receptor tyrosine kinases, RTKs), the receptors for Bv8 and EG-VEGF belong to the GPCR family and are not drug targets for tyrosine kinase inhibitors (TKIs) [68, 69]. This may also be one of the reasons why tumors get TKI therapy-resistant. (Fig. 3C)

Recent studies have found that TANs produce Osteopontin (OPN) and MMP14promoting EC chemotaxis and accelerating vascular network formation, respectively [72]. OPN maintains EC survival through activation of the PI3K-AKT pathway, followed by Bcl-xL upregulation and NF-κB activation [72, 73]. Meanwhile, OPN also enhances VEGF expression through the AKT and ERK pathways, which in turn acts as a positive feedback signal activating PI3K/AKT and ERK pathways, enhancing angiogenesis directly [73]. The pro-angiogenic effect of MMP14 is associated with VEGFR1 [74]. In ECs, VEGFR1 is considered as a negative regulator of VEGFR2 [62]. Compared to VEGFA/VEGFR2 interaction, VEGFA has a stronger affinity for VEGFR1 but a weaker ability to induce VEGFR1 phosphorylation [62]. MMP14 can bind selectively and then degrade VEGFR1 on the surface of ECs, thereby enhancing the sensitivity of VEGFR2 to VEGFA, resulting a strong proliferation effect on ECs at low concentrations of VEGFA [74]. (Fig. 3C)

In addition to their pro-angiogenic role, ECs can also affect neutrophil adhesion in TME. Co-culture experiments showed that crosstalk between neuroblastoma cells and ECs downregulates adhesion molecule CD44R expression impairing neutrophil adhesion and invasion, blocking neutrophil recruitment to ECs [75]. Researchers suggested that this might be a tumor escape strategy [75]. Interestingly, the addition of isolated tumor cell membrane fragments to ECs rather than soluble cell culture supernatant caused this effect, suggesting that the interaction of ECs with tumor cells is cell-cell direct contact [75]. This process may be related to the PKC signaling pathway, and blocking PKC can prevent the reduction in neutrophil binding capacity [75]. (Fig. 3C)

TANs promote PN-MES transition

GB has been classified into 4 molecular subtypes—Proneural (PN), Mesenchymal (MES), Classical (CL), and Neural (NL). The NL type has been recognized as a contamination of specimens by normal neurons and has been excluded from the most recent classifications [76–78]. Compared to the PN-type, MES-type GB is more aggressive and has a worse prognosis [79]. Presently, most studies have suggested that the critical signaling pathways driving the PN-MES transition (PMT) include STAT3, JAK, and NF-κB pathways, involving various activated molecules such as CXCLs, growth factors, and neurotransmitters [77, 79]. The prevailing view is that the crosstalk between TAMs and GB cells plays a pivotal role in PMT [77, 79, 80]. However, some recent evidence has suggested that TANs also play an indispensable and crucial role in PMT.

Dysregulated expression of the S100 protein family is a common feature in human cancers [81]. S100A4, an important member of the S100 protein family, plays a significant role in tumor progression, metastasis, and mesenchymal transition [82]. Liang et al. have indicated that MES-type GB significantly overexpresses S100A4, whereas the PN type downregulates S100A4 expression [83]. Meanwhile, consistent with the finding that neutrophils can increase S100A4 expression in vitro, S100A4 was significantly co-expressed with CD64 in samples from GB patients, which collectively suggests that TANs promote PMT in GB by facilitating the expression of S100A4 [83]. Chow et al. further identified S100A4 as an upstream regulator of other PMT modulators, such as SNAIL2 and ZEB, which have been explicitly identified to promote the invasion and mesenchymal transition of GB [84]. (Fig. 3D)

Another strong evidence comes from Chen et al. They used CRISPR/Cas9 technology to knock out monocyte chemoattractant protein (MCP) to abolish TME recruitment to monocytes [85]. In a platelet-derived growth factor B (PDGFB)-driven GB model, monocyte depletion was accompanied by a massive influx of neutrophils into the TME and elevation of the neutrophil chemokines CXCL1 and CXCL2. In contrast, these phenomena were not present in the Nf1-silenced GB model [85]. Further experiments demonstrated that neutrophil-derived TNF-α directly drives the mesenchymal transition of PDGFB-driven primary GB cells [85]. (Fig. 3D)

Fig. 3 TANs participate in malignant behaviors of glioma cells (A) NETs assist NE and MMP9 in the catabolism of Laminin, which ultimately promotes the arousal of dormant glioma cells and promotes glioma invasion. (B) TANs produce mtROS, NE, BMP2, TGF-β2, regulate ferroptosis resistance or ferroptosis of tumor cells promoting tumor proliferation. (C) TANs secrete BV8, IL-8, VEGFA, MMP14 and OPN, promoting tumor angiogenesis via influencing EC. Tumor cell-EC interaction reduces neutrophil recruitment. (D) TANs promote PMT of glioma

Interaction of TANs with TME niches and components

Hypoxia

Hypoxia is a common niche in solid tumors and is no exception in glioma. The hypoxia-inducible factor (HIF) family, as crucial transcription factors, become activated under hypoxic conditions, regulating various hypoxia-responsive genes to support cell survival in hypoxic environments [86–88]. Other transcription factors such as NF-κB also play vital roles and crosstalk with HIF [89]. Studies have found that in highly heterogeneous tumors, low oxygen signaling, and hypoxia-related genes are more prevalent, correlating with poorer prognoses [90]. Therefore, elucidating the role of the hypoxic niche in tumor progression is both important and necessary.

Hypoxia typically arises due to rapid cancer cell proliferation and the lack of sufficient oxygen-supplying blood vessels [91]. Correspondingly, hypoxia can induce angiogenesis through various signaling pathways, including directly inducing angiogenic factors within tumor cells and indirectly recruiting pro-angiogenic cells [86]. Studies have suggested that hypoxia can induce tumor cells to produce IL-8, one of the key cytokines involved in TANs recruitment [92]. It has also been found that hypoxia induces tumor cells to produce many extracellular vesicles (EVs), which transport amounts of IL-8 and miR-451 [93]. Although it has not been described that hypoxia-derived EV directly affects neutrophil function, the EVs intrinsic IL-8 and miR-451 have been described to play opposite roles in neutrophil recruitment [93]. As mentioned above, IL-8/CXCR1/2 signaling promotes neutrophil recruitment to the TME. Moreover, IL-8 acts as a neutrophil activator that activates the MAPK signaling pathway, inhibits neutrophil apoptosis and enhances neutrophil proliferation [94]. On the contrary, miR-451 inhibits the phosphorylation of p38 MAPK and suppresses neutrophil chemotaxis [95]. Further studies on the specific effects of EVs are needed. Triner et al., in addition, have found that the CXCL1 gene is upregulated in colon cancer in a HIF2α-dependent manner, recruiting TANs through the CXCL1/CXCR2 signaling to promote colorectal cancer progression [96]. Recent studies have discovered that GB, under hypoxic conditions, can produce acrolein, inhibiting neutrophil activation and promoting N2 TANs phenotype [97]. Acrolein can produce TGF-β-like effects, promoting neutrophil expression of Arg1, inhibiting MPO expression, superoxide production and ROS generation, inhibiting tumor-killing activity, and inducing N2 phenotype polarization [97]. Dimercaprol, which is a kind of acrolein scavenger, can inhibit tumor growth significantly [97]. Further studies have shown that acrolein modifies the Cys310 residue in AKT, which is a key residue in the catalytic structural domain of AKT [97]. This modification by acrolein inhibits AKT phosphorylation, blocks the downstream signaling pathway of PI3K/AKT and inhibits neutrophil activation [97]. Overall, the interaction between hypoxia and neutrophils results in pro-tumor genesis. (Fig. 4A).

TAMs

Concerning brain tumors, the concept of TAMs is generally broadened into two cell types: circulating monocyte/macrophage and resident microglia within the central nervous system [98, 99]. TAMs represent most immune cells within the brain tumor microenvironment, constituting up to 30% of the tumor mass [7]. This process may be related to the PKC signaling pathway, and blocking PKC can prevent the reduction in neutrophil binding capacity [100]. The conventional view is that TAMs exist in two polarized states, M1-like (classically activated), which is usually anti-tumor, and M2-like (alternatively activated), which is usually pro-tumor [99]. A novel view, on the other hand, suggests that the M1/M2-like classification inadequately reflects the actual states of TAMs in vivo, thus classifying them into immunosuppressive cells and proliferative macrophages by molecular subtype and functional state [101]. This can help us better understand the role of TAMs in TME.

The interaction between TANs and TAMs has been established in various solid tumors. It promotes oncostatin M and IL-11 associated tumor progression in intrahepatic cholangiocarcinoma (ICC) and post-treatment progression in NSCLC [102, 103]. Researchers have also identified antitumor outcomes resulting from the TANs-TAMs interaction. In dermal sarcoma models, TANs promote TAMs to produce IL-12, subsequently activating the IFN-γ pathway in αβT cells, generating an antitumor effect [104]. But unfortunately, in glioma, studies on TANs-TAMs interactions remain largely unexplored. Researchers tend to focus more on the interactions of TANs or TAMs, separately, with glioma cells and other cells, even though there is overlap in the cytokines expressed or received by TANs and TAMs (such as CCR2, TGF-β, IFN-γ, VEGF, GM-CSF, etc.) [98, 99, 105]. It has been shown that OPN produced by glioma stem cells recruits both TANs and TAMs to glioma TME [106]. It has also been suggested that TANs can promote biopsy-induced glioma cell metastasis by recruiting TAMs [28]. Additionally, an interesting and yet unresolved issue is that, apart from the MES subtype of GBM, TANs recruitment in glioma appears to be repulsed by TAMs. This pattern differs from what is observed in infections or other tumors, where monocytes/macrophages produce neutrophil chemokines to recruit neutrophils [10]. In short, the TANs-TAMs interaction in glioma is a worth exploring research direction. (Fig. 4B)

T-cell

The dysfunction of T-cell is the most important mechanism behind the immune suppression in glioma [99]. TANs produce a high level of ROS that can enter T-cell, damaging telomeres in DNA, accelerating T-cell aging, consequently leading to T-cell dysfunction [107]. Arginine is a crucial factor for sustaining T-cell activation, and Arginase 1 (Arg1) released by TANs extracellularly significantly depletes extracellular L-arginine, causing T-cell dysfunction [108]. This mechanism often results in systemic T-cell suppression in GB patients [108].

The interaction between the programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) represents the classical T-cell immune checkpoint that acts as a “brake” on immune function [109]. In glioma, this pathway serves as a significant mechanism causing T-cell suppression [110]. Sequential IF studies have shown that CD4+ T helper cell, Treg, and CD8+ T-cell are closer to TANs than to other TME cells [111]. Meanwhile, PD-L1+ TANs were closest to PD-1+CD8+ T-cell and the most abundant PD-L1+ cell type within the PD-1+CD8+ T-cell niche was TANs [111]. This stands as critical evidence of TANs-mediated immune suppression in glioma TME. Furthermore, TANs can induce PD-1 expression on CD4+ effector memory T-cell (TEM) within the GB microenvironment. Simultaneously, TANs exhibit high levels of PD-L1, depleting CD4+ TEM function through the PD-1/PD-L1 axis, promoting immune suppression [112]. In a certain GB model with defective type I IFN receptor, tumor-infiltrating CD11b+Ly6G+ cell increase, while CD4+FoxP3+ cell (immunosuppressive Treg) increase and CD8+ cytotoxic T cell (CTL) decrease [113]. Ferroptosis also plays an important role in T-cell related immunosuppression. Ferroptosis is a non-apoptotic, regulated cell death triggered by dysregulation of redox mechanisms. New studies have shown that TANs are highly susceptible to ferroptosis and even spontaneously undergoes ferroptosis [114]. Meanwhile, ferroptosis accounts for most of the death program in TANs [114]. Ferroptosis in TANs can generate a large amount of PGE2 and oxidized phosphatidylethanolamine (ox-PE), which collectively inhibit CD8 + T cell activity, producing immunosuppression [114] (Fig. 4C).

Interestingly, the interaction between TAN and T-cell also exhibits some antitumor effects. In lung cancer, TANs with an antigen-presenting cell (APC)-like phenotype trigger antitumor T-cell responses and support anticancer activity [21]. Lad et al. have reported a specific population of TANs with DC characteristics [20]. These particular TANs, originating from the local cranial bone marrow, accumulate in the GB microenvironment, can activate T-cell cytotoxicity and memory, inhibiting tumor growth in vivo [20]. Recent findings provide strong support for this anti-tumor effect and have made great strides. Wu et al. analyzed the transcriptional profile of TANs and classified them into 10 different states, of which HLA-DR+ TANs express MHC class II molecules and exhibit antigen-presenting properties [8]. Co-culture experiments have shown that HLA-DR+ TANs can present tumor neoantigens and activate T-cell directly through ligand-receptor interactions, then stimulate T-cell to express TNFα and generate reactive T-cell responses [8]. According to metabolic analysis, leucine catabolism leads to high HLA-DR expression and initiates antigen presentation mechanisms [8]. Leucine diet combined with anti-PD-1 therapy significantly reduces tumor volume and stabilizes the disease [8]. (Fig. 4C)

Fig. 4 Crosstalk between TANs and glioma microenvironment niches and components (A) Hypoxia stimulates glioma cells to produce IL-8, CXCL1 and Acrolein, promoting neutrophil recruitment and N2-type transformation. (B) TANs and TAMs interaction upregulate STAT3 signaling in tumor cells resulting in protumor effect; CCL3+ TANs and SPP1+ TAMs interaction promotes post-therapy tumor progression; TANs promote TAMs IL-12 secretion activating IFN-γ signaling in αβ T-cell, leading to antitumor effect. (C) TANs led to immunosuppression via T-cell dysfunction, ICB and ferroptosis; DC-like TANs and HLA-DR+ TANs exert an antitumor effect

TANs promote glioma therapy resistance

TANs promote RT resistance in glioma

As the infiltration of tumor cells extends far beyond the lesion, postoperative RT is an important part of glioma treatment, helping to preserve patient function and improve survival [5]. Several studies have demonstrated that TANs are involved in promoting glioma RT resistance [115]. Radiation-induced senescent GB cells recruit TANs and promote angiogenesis via NF-κB signaling [115, 116]. Meanwhile, TANs support GB to glioma stem cells transformation through NOS2-NO-ID4 signaling [115, 116]. In addition, TANs secrete S100A4, which promotes glioma stem cells proliferation and stemness and facilitates RT resistance formation [83, 115]. In lung cancer model, researchers have found that lung cancer cells upregulate GLUT1 expression in TAN, which promotes TANs survival and RT resistance [117]. Increased sensitivity of lung cancer to RT was observed in the TANs GLUT1 knock-out lung cancer mouse model [117].

TANs promote anti-angiogenesis therapy resistance in glioma

TKIs, whose main targets are RTKs, such as EGFR, PDGFR, VEGFR, and are commonly used anti-angiogenic agents that effectively inhibit glioma proliferation and invasion [118]. TANs can produce substances such as VEGFA, MMP9, MMP14, OPN, etc., which enhance VEGFA/VEGFR interaction that promotes glioma angiogenesis. This pro-angiogenic effect largely cuts down the therapeutic efficacy of TKIs or requires larger doses of TKIs to achieve the same efficacy [19]. In addition to VEGF, TANs also produce Bv8 to promote tumor angiogenesis. Unlike VEGFR, the receptor for Bv8 belongs to the GPCR family, therefore, TKIs cannot inhibit the pro-angiogenic effect produced by Bv8, resulting in TKIs resistance in tumors [68, 69]. Several studies based on different solid tumors corroborate this and find that inhibiting TANs can enhance the efficacy of TKIs [119–121]. Additional studies have demonstrated that TANs mediate glioma resistance to anti-angiogenic therapy by promoting glioma mesenchymal transition. de Groot JF and colleagues compared acquired bevacizumab-resistant versus non-resistant GB subtypes and found a highly significant correlation between acquired resistance to anti-VEGF therapy and mesenchymal features in GB [122]. Subsequently, they determined that TANs promote GB mesenchymal transition through S100A4 and discovered that S100A4 knockdown neutrophils attenuated mesenchymal transformation and angiogenesis of GB by not affecting neutrophil proliferation [83]. Hence, a combination therapy involving S100A4 inhibitors may be a viable option to counteract resistance to anti-angiogenic therapy in glioma. No relevant clinical/preclinical trials were retrieved, and the specific effects of this regimen need to be further investigated.

TANs promote immune checkpoint blockade therapy resistance in glioma

Immune checkpoint blockade (ICB) has shown remarkable success in various solid tumors, but good efficacy has not been observed in glioma, an important reason being the presence of significant immunosuppression in glioma [123, 124]. Blocking the PD-1/PD-L1 axis represents one of the classic ICB therapies. PD-1 is primarily expressed in activated T-cells and its interaction with PD-L1 reduces the immune response of T-cells [109, 124]. Commonly used drugs include PD-1 antibodies such as Nivolumab, Pembrolizumab, and emerging PD-L1 antibodies such as Atezolizumab [124, 125]. However, a prerequisite for these therapies to be effective is that T-cells possess (at least to some extent) normal functionality. As mentioned earlier, TANs in the glioma microenvironment can cause T-cell dysfunction through various pathways, particularly depleting the functionality of CD4+TEM via the PD-1/PD-L1 axis [107, 108, 112, 113]. These can promote glioma treatment resistance to ICB.

Therapies targeting TANs

Anti-angiogenesis therapy

Presently, the standard therapy for newly diagnosed glioma involves surgical resection followed by radiotherapy plus TMZ combined chemotherapeutic treatment [5, 126]. However, almost all patients experience recurrence [5, 126]. Bevacizumab, an anti-VEGF antibody, has been approved for treating recurrent glioma in several countries, including the United States [5]. Nonetheless, current clinical trials have not shown distinct advantages of bevacizumab. Although the use of bevacizumab improves PFS, the OS of patients was not improved compared to standard therapy [127, 128]. Apart from bevacizumab, regorafenib has shown promising progress in recent studies. Regorafenib is an orally available multikinase inhibitor used against angiogenesis, stromal, and RTK [129]. In a phase II clinical trial, regorafenib, when compared to lomustine (TMZ analog), increased the median OS from 5.6 to 7.4 months, with a comparable rate of severe adverse events [129]. Regorafenib might be a potential novel therapy. (Table 1)

Table 1 Clinical trials targeting TANs and/or its correlating agents

Target	Drugs	Phase	Results/Conclusions	Identifier	Ref.	
RTK	Regorafenib	II	Regorafenib showed an encouraging OS benefit in recurrent GB	NCT02926222	[129]	
VEGF	Bevacizumab	III	The addition of bevacizumab to RT-TMZ did not improve survival in patients with GB but improved PFS. However, the rate of adverse events was higher with bevacizumab than with placebo	NCT00943826	[127]	
N/A	First-line use of bevacizumab did not improve OS in patients with newly diagnosed GB. PFS was prolonged but did not reach the prespecified improvement target	NCT00884741	[128]	
PD-1/VEGF	Nivolumab/

Bevacizumab

	III	Mediate OS was comparable between nivolumab and bevacizumab in the overall patient population with recurrent GB	NCT02017717	[130]	
PD-1	Nivolumab	III	Nivolumab added to RT + TMZ did not improve survival in patients with newly diagnosed GB with methylated or indeterminate MGMT promoter	NCT02667587	[126]	
II	Neoadjuvant nivolumab supporting a local immunomodulatory effect of treatment	NCT02550249	[134]	
Nivolumab, pembrolizumab	Early phase	Neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response	N/A	[133]	
Pembrolizumab	Ib	Pembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with manageable toxicity in this small, signal-finding, recurrent GB cohort	NCT02054806	[131]	
Pembrolizumab with oncolytic DNX-2401	I/II	The combination of intratumoral DNX-2401 followed by pembrolizumab was safe with notable survival benefits in select patients	NCT02798406	[135]	
PD-L1 & VEGF	Durvalumab & Bevacizumab	II	PD-L1 blockade and combination with standard or reduced dose bevacizumab was ineffective	N/A	[132]	
PD-L1 & CTLA-4	Nivolumab & Ipilimumab	I	Intracerebral administration of nivolumab and ipilimumab following maximal safe resection of recurrent GB was feasible, safe, and associated with encouraging OS	NCT03233152	[136]	
IL-8 (CXCL8)	BMS-986253	Early phase & I	BMS-986253 reduces IL-8 levels, neutrophils recruitment and attenuates mesenchymal transition	NCT02536469	[137, 138]	
CXCR2	MK-7123	II	Blocking CXCR2 reduced neutrophil counts and improved lung function in COPD patients	NCT01006616	[139]	
Reparixin & Paclitaxel	Ib/II	Weekly paclitaxel plus reparixin in MBC appeared to be safe and tolerable, with demonstrated responses in the enrolled population	NCT02001974

NCT02370238

	[140]	
SB225002	Early phase	The CXCR2-antagonist inhibited glioma growth during tumor initiation and progression, whereas treatment was well-tolerated by the recipients	N/A	[141]	
TGF-β	Galunisertib	Ib/IIa	Adding galunisertib into TMZ-based radiochemotherapy has no differences in efficacy, safety, or pharmacokinetic variables	NCT01220271	[143]	
II	Galunisertib + lomustine failed to demonstrate improved OS relative to placebo + lomustine	NCT01582269	[145]	

PD-1/PD-L1 blockade

PD-1/PD-L1 blockade has shown significant efficacy in many tumors but remains limited effective in glioma. The classic PD-1 monoclonal antibody nivolumab has efficacy comparable to bevacizumab [130]. Combining nivolumab with standard therapy does not influence patient survival [126]. Single-agent use of the PD-1 antibody pembrolizumab is effective for only a small subset of recurrent GB patients [131]. The combination of the PD-L1 antibody durvalumab with bevacizumab has proven ineffective [132]. These less optimistic results encourage researchers to explore new directions. Several studies have shown that adjuvant or neoadjuvant PD-1 monoclonal antibodies, such as nivolumab and pembrolizumab, can enhance the anti-tumor immune response of glioma patients, resulting in a positive effect on glioma treatment [133, 134]. Pembrolizumab combined with DNX-2401, an oncolytic virus capable of inducing an anti-tumor immune response in patients, has shown significant survival benefits for some glioma patients [135]. Furthermore, innovative delivery methods are potential avenues of development. A phase I clinical trial has confirmed that intracerebral administration of nivolumab and CTLA-4 inhibitor ipilimumab after maximal safe resection is feasible, safe, and has a positive effect on OS [136]. Recent studies have found that leucine stimulates TANs to highly express HLA-DR+, present tumor neoantigens and stimulate T cells to produce reactive T cell responses [8]. Animal studies have shown that a leucine diet combined with anti-PD-1 therapy significantly reduces tumor volume and stabilizes the disease [8]. (Table 1)

Targeting CXCLs-CXCR1/2 signaling

IL-8 (CXCL8) plays an important role in neutrophil recruitment to TME and is involved in tumor malignant behavior. Pre-clinical studies have shown that the IL-8 antagonist BMS-986253 significantly reduces neutrophil recruitment and attenuates mesenchymal transition in triple-negative breast cancer [137]. Phase I studies have found that BMS-986253 significantly reduces IL-8 levels and is being evaluated in combination therapy with immune checkpoint inhibitors (NCT02536469) [138]. CXCR2 is an essential neutrophil chemotactic factor receptor, recruiting neutrophils to the TME and regulating TANs participation in tumor angiogenesis [25]. CXCR1 also plays an important role in neutrophil recruitment [35]. In addition, the efficacy of CXCR1/2 antagonists in the treatment of non-neoplastic diseases has been demonstrated. For example, a phase II study demonstrated that MK-7123, a CXCR2 antagonist, significantly reduced neutrophil counts and significantly improved lung function in COPD patients (NCT01006616) [139]. Using CXCR2 antagonists for tumor therapy is a promising strategy, and this has shown good progress in clinical trials of Reparixin for breast cancer (NCT02001974, NCT02370238) [140]. A study using a CXCR2 antagonist (SB225002) in high-grade glioma demonstrated its potential to inhibit tumor growth during tumor development and progression [141]. (Table 1)

Targeting TGF-β signaling

TGF-β signaling plays a crucial role in glioma, inducing TANs to polarize toward the N2 type (pro-tumor), and several downstream signaling pathways are involved in tumor progression [38]. The use of TGF-β antagonists for the treatment of glioma is theoretically a viable option. Galunisertib (LY2157299 monohydrate) is a small molecule TGF-β-R1 kinase inhibitor that displays anti-tumor effects in GB animal models [142–144]. A phase I/II clinical trial has indicated that combining 300 mg/d of Galunisertib with TMZ chemotherapy can improve OS for GB patients [143]. Another phase II clinical trial has demonstrated that in recurrent GB patients, the treatment with Galunisertib plus lomustine did not improve OS compared to placebo plus lomustine treatment [145]. The specific efficacy of TGF-β blockade in glioma requires further investigation. (Table 1)

Targeting the S100 protein family

Multiple members of the S100 protein family exhibit dysregulated expression in cancer [81]. As mentioned above, TANs promote glioma metastasis through S100A4 [83]. Single-cell analysis has suggested that S100A4 could be a target for glioma immunotherapy [146]. Feng et al. have found that Allopregnanolone, a physiological neural modulator, significantly downregulates several proteins in GB, including S100A4 and S100A11, inhibiting GB cell survival [147]. An in vitro study has indicated that downregulating S100A12 (primarily expressed by neutrophils) significantly inhibits glioma cell growth [148]. These studies imply that the S100 protein family might be key molecular targets to explore new directions in glioma treatment.

Targeting NETs

NETs play a crucial role in the progression of various cancers, and targeting NETs is a potential new treatment direction. However, most of these studies have remained at the mechanistic level and have not achieved breakthrough progress [48]. In one study, NETs have led to endothelial dysfunction in advanced glioma patients, promoting a hypercoagulable state, which is necessary to cause the complication of venous thromboembolism (VTE) [149]. Researchers subsequently found that in vitro, the combination of DNase I and activated protein C significantly reduced endothelial dysfunction [149]. Furthermore, there is evidence suggesting that NETs might exhibit an anti-tumor effect [150]. Overall, although there is substantial evidence supporting the therapeutic targeting of NETs, we recommend consulting in-depth reviews on neutrophils, NETs, and cancer for more information [48, 49, 150–152].

Neutrophil-based drug delivery systems

Neutrophil-based drug delivery systems are a promising targeted cancer therapy strategy, primarily divided into two types: those utilizing neutrophils as carriers and neutrophil membrane-driven nanovesicles [153]. The most significant advantage of this system is its natural ability to traverse the blood-brain barrier (BBB) as neutrophils naturally recruit to the tumor microenvironment. In recent years, studies utilizing this system for glioma treatment have made significant progress. Wang et al. have reported a neutrophil-exosome system targeting the inflamed tumor microenvironment, showing success in crossing the BBB and infiltrating tumor tissues in a GB animal model loaded with doxorubicin in response to inflammatory stimuli [154]. Zhang et al. have reported a neutrophil-based micro-robot (neutrobot) capable of actively delivering drugs to malignant glioma [155]. Using magnetic drug-loaded particles phagocytosed by neutrophils and their chemotactic movement along inflammatory gradients, precise drug delivery significantly suppressed tumor cell proliferation [155]. Although emerging chimeric antigen receptor (CAR)-T cell therapy has been successful in many cancers, its effectiveness in gliomas is limited due to the difficulty of T cells crossing the BBB [156]. Recently, Chang et al. have engineered CAR-neutrophils using CRISPR/Cas9 in human pluripotent stem cells, targeting GB, delivering and releasing nanomedicines to kill tumor cells, prolonging the lifespan of mouse models, contributing to the application of CAR therapy in intracranial tumors [156].

Conclusions and perspectives

In this review, we provide a comprehensive description of the functions and mechanisms of TANs in glioma progression. In most cases, TANs exhibit a pro-tumoral N2 phenotype, promoting glioma cell proliferation, invasion, PN-MES transition, and resistance to radiotherapy and chemotherapy through paracrine and other forms [54]. It is important to note that the role of TANs in tumor progression is context-dependent, TANs can also adopt an anti-tumoral N1 phenotype that inhibits tumor growth [11]. In addition to tumor heterogeneity, the different phenotypes of TANs may be related to the time at which they are recruited into the tumor microenvironment, where they are more likely to exhibit an N1 phenotype at early stages and are gradually induced by the tumor microenvironment to an N2 phenotype over time. Furthermore, a large number of bioinformatic analysis studies have reported a series of new genes or genesets associated with the proportion of TANs infiltration in gliomas and the prognosis of glioma patients, which we have summarized in this paper. However, most of these reports are phenotypic studies, the mechanisms of the above genes and genesets on the infiltration and function of TANs still need in-depth elucidation.

Gliomas are hallmarked by their complex tumor microenvironments [157]. The extensive crosstalk between tumor cells and microenvironmental components within the glioma microenvironment and the formation of positive feedbacks that promote tumor growth and malignant progression, which are important causes of recurrence and treatment resistance in gliomas [157]. In this review, we focus on elucidating the interactions between glioma microenvironment components and TANs and their effects on tumor progression, including the hypoxic microenvironment, vascular endothelial cells, TAMs and T cells. TANs have extensive interactions with multiple microenvironmental components and are essential for maintaining their pro-tumoral N2 phenotype. Therefore, further investigation into the role of TANs in tumor progression and the development of targeted therapies, whether for gliomas or other malignancies, should take full account of the microenvironment in which TANs and tumor cells reside in the tumor, in conjunction with existing tools such as spatial transcriptomics.

Finally, we summarize current advances in TANs-based anti-tumor therapies. Although TANs are highly promising anti-glioma targets, because the mechanism TANs in glioma progression is still largely unclear, there are currently fewer targets that can specifically target TANs within tumors, and even fewer corresponding clinical trials. As the mechanism TANs continues to be elucidated, more therapies targeting TANs will become available for the clinical treatment of gliomas and other tumors, both alone and in combination with therapies including immune checkpoint inhibitors. Additionally, the treatment of glioma with drug delivery systems based on neutrophils represents a promising research direction that requires further refinement through more clinical experiments.

Acknowledgements

Not applicable.

Author contributions

Jiayi Wen: writing-original manuscript preparation, figure visualization. Dan Liu: writing-original manuscript preparation, reviewing and editing. Hongtao Zhu: writing-reviewing and editing, supervision, funding acquisition. Kai Shu: writing-reviewing and editing, supervision, validation, funding acquisition.

Funding

This work was supported by grants from the National Key R&D Program of China, MOST (2023YFC2510000) to Kai Shu, the National Natural Science Foundation of China (82403476) to Hongtao Zhu, the Hubei Association for Science and Technology Young Talents Support Projects (2024) to Hongtao Zhu, the China Postdoctoral Science Foundation (2022M711253) to Hongtao Zhu, Hubei Natural Science Foundation (2023AFB135) to Hongtao Zhu, and the postdoctoral innovation research position funding of Hubei province (2022) to Hongtao Zhu.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Abbreviations

APC Antigen-presenting cell

Arg Arginine

Arg1 Arginase 1

BBB Blood-brain barrier

BMP2 Bone morphogenetic protein 2

CAR Chimeric antigen receptor

CCL C-C motif ligand 3

CL Classical

CTL Cytotoxic T cell

CXCLs CXC motif ligands

CXCR CXC chemokine receptor

DCs Dendritic cells

ECM Extracellular matrix

ECs Endothelial cells

EVs Extracellular vesicles

EG-VEGF Endocrine gland-derived vascular endothelial growth factor

GB Glioblastoma

G-CSF Granulocyte colony-stimulating factor

G-CSF-R Granulocyte colony-stimulating factor receptor

GM-CSF Granulocyte-macrophage colony-stimulating factor

HCC Hepatocellular carcinoma

HIF Hypoxia-inducible factor

ICAM-1 Intercellular cell adhesion molecule-1

ICB Immune checkpoint blockade

ICC Intrahepatic cholangiocarcinoma

IDH Isocitrate dehydrogenase

IFN Interferon

IL Interleukin

iNOS Inducible nitric oxide synthase

IRS-1 Insulin receptor substrate-1

MCP Monocyte chemoattractant protein

MES Mesenchymal

MMP9 Matrix metalloproteinase 9

MPO Myeloperoxidase

mtROS Mitochondrial reactive oxygen species

mu-IDH Mutant isocitrate dehydrogenase

NE Neutrophil elastase

NETs Neutrophil extracellular traps

NL Neural

NLR Neutrophil-to-lymphocyte ratio

NSCLC Non-small cell lung cancer

OPN Osteopontin

OS Overall survival

ox-PE Oxidized phosphatidylethanolamine

PBNs Peripheral blood neutrophils

PD-1 Programmed cell death receptor-1

PDGFB Platelet-derived growth factor B

PDGFR Platelet-derived growth factor receptor

PD-L1 Programmed cell death receptor 1 ligand-1

PFS Progression-free survival

PGE2 Prostaglandin E2

PMT Proneural-mesenchymal transition

PN Proneural

RT Radiotherapy

RTKs Receptor tyrosine kinases

TANs Tumor-associated neutrophils

TAMs Tumor-associated macrophages

TEM Effector memory T-cell

TGF-β Transforming growth factor-β

TIMP-1 Tissue inhibitors of metalloproteinase-1

TKIs Tyrosine kinase inhibitors

TLRs Toll-like receptors

TME Tumor microenvironment

TMZ Temozolomide

TNBC Triple-negative breast cancer

TNF-α Tumor necrosis factor-α

VEGF Vascular endothelial growth factor

VEGFA Vascular endothelial growth factor A

VEGFR Vascular endothelial growth factor receptor

VTE Venous thromboembolism

wt-IDH Wild-type isocitrate dehydrogenase

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jiayi Wen and Dan Liu contributed equally to this work.
==== Refs
References

1. Ostrom QT Bauchet L Davis FG Deltour I Fisher JL Langer CE Pekmezci M Schwartzbaum JA Turner MC Walsh KM The epidemiology of glioma in adults: a state of the science review Neuro Oncol 2014 16 896 913 10.1093/neuonc/nou087 24842956
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, et al. The epidemiology of glioma in adults: a state of the science review. Neuro Oncol. 2014;16:896–913.24842956
2. Ostrom QT Patil N Cioffi G Waite K Kruchko C Barnholtz-Sloan JS CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2013–2017 Neuro Oncol 2020 22 iv1 96 10.1093/neuonc/noaa200 33123732
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22:iv1–96.33123732
3. Louis DN Perry A Wesseling P Brat DJ Cree IA Figarella-Branger D Hawkins C Ng HK Pfister SM Reifenberger G The 2021 WHO classification of tumors of the Central Nervous System: a summary Neuro Oncol 2021 23 1231 51 10.1093/neuonc/noab106 34185076
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al. The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231–51.34185076
4. Kotecha R Odia Y Khosla AA Ahluwalia MS Key clinical principles in the management of Glioblastoma JCO Oncol Pract 2023 19 180 9 10.1200/OP.22.00476 36638331
Kotecha R, Odia Y, Khosla AA, Ahluwalia MS. Key clinical principles in the management of Glioblastoma. JCO Oncol Pract. 2023;19:180–9.36638331
5. Weller M van den Bent M Preusser M Le Rhun E Tonn JC Minniti G Bendszus M Balana C Chinot O Dirven L EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Nat Reviews Clin Oncol 2021 18 170 86 10.1038/s41571-020-00447-z
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Reviews Clin Oncol. 2021;18:170–86.
6. van Solinge TS Nieland L Chiocca EA Broekman MLD Advances in local therapy for Glioblastoma - taking the fight to the tumour Nat Rev Neurol 2022 18 221 36 10.1038/s41582-022-00621-0 35277681
van Solinge TS, Nieland L, Chiocca EA, Broekman MLD. Advances in local therapy for Glioblastoma - taking the fight to the tumour. Nat Rev Neurol. 2022;18:221–36.35277681
7. Quail DF Joyce JA The Microenvironmental Landscape of Brain tumors Cancer Cell 2017 31 326 41 10.1016/j.ccell.2017.02.009 28292436
Quail DF, Joyce JA. The Microenvironmental Landscape of Brain tumors. Cancer Cell. 2017;31:326–41.28292436
8. Wu Y Ma J Yang X Nan F Zhang T Ji S Rao D Feng H Gao K Gu X Neutrophil profiling illuminates anti-tumor antigen-presenting potency Cell 2024 187 1422 e14391424 10.1016/j.cell.2024.02.005 38447573
Wu Y, Ma J, Yang X, Nan F, Zhang T, Ji S, Rao D, Feng H, Gao K, Gu X, et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell. 2024;187:1422–e14391424.38447573
9. Klemm F Maas RR Bowman RL Kornete M Soukup K Nassiri S Brouland JP Iacobuzio-Donahue CA Brennan C Tabar V Interrogation of the Microenvironmental Landscape in Brain Tumors reveals Disease-specific alterations of Immune cells Cell 2020 181 1643 10.1016/j.cell.2020.05.007 32470396
Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, Brouland JP, Iacobuzio-Donahue CA, Brennan C, Tabar V, et al. Interrogation of the Microenvironmental Landscape in Brain Tumors reveals Disease-specific alterations of Immune cells. Cell. 2020;181:1643–.32470396
10. Friedmann-Morvinski D, Hambardzumyan D. Monocyte-neutrophil entanglement in glioblastoma. J Clin Invest 2023, 133.
11. Giese MA Hind LE Huttenlocher A Neutrophil plasticity in the tumor microenvironment Blood 2019 133 2159 67 10.1182/blood-2018-11-844548 30898857
Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133:2159–67.30898857
12. Massara M Persico P Bonavita O Mollica Poeta V Locati M Simonelli M Bonecchi R Neutrophils in Gliomas Front Immunol 2017 8 1349 10.3389/fimmu.2017.01349 29123517
Massara M, Persico P, Bonavita O, Mollica Poeta V, Locati M, Simonelli M, Bonecchi R. Neutrophils in Gliomas. Front Immunol. 2017;8:1349.29123517
13. Masucci MT Minopoli M Carriero MV Tumor Associated neutrophils. Their role in Tumorigenesis, Metastasis, Prognosis and Therapy Front Oncol 2019 9 1146 10.3389/fonc.2019.01146 31799175
Masucci MT, Minopoli M, Carriero MV. Tumor Associated neutrophils. Their role in Tumorigenesis, Metastasis, Prognosis and Therapy. Front Oncol. 2019;9:1146.31799175
14. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis 2012, 33:949–55.
15. Gregory AD Houghton AM Tumor-associated neutrophils: new targets for cancer therapy Cancer Res 2011 71 2411 6 10.1158/0008-5472.CAN-10-2583 21427354
Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71:2411–6.21427354
16. Coffelt SB Wellenstein MD de Visser KE Neutrophils in cancer: neutral no more Nat Rev Cancer 2016 16 431 46 10.1038/nrc.2016.52 27282249
Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16:431–46.27282249
17. Amankulor NM Kim Y Arora S Kargl J Szulzewsky F Hanke M Margineantu DH Rao A Bolouri H Delrow J Mutant IDH1 regulates the tumor-associated immune system in gliomas Genes Dev 2017 31 774 86 10.1101/gad.294991.116 28465358
Amankulor NM, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M, Margineantu DH, Rao A, Bolouri H, Delrow J, et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017;31:774–86.28465358
18. De Palma M Biziato D Petrova TV Microenvironmental regulation of tumour angiogenesis Nat Rev Cancer 2017 17 457 74 10.1038/nrc.2017.51 28706266
De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17:457–74.28706266
19. Bui TM Yalom LK Sumagin R Tumor-associated neutrophils: orchestrating cancer pathobiology and therapeutic resistance Expert Opin Ther Targets 2021 25 573 83 10.1080/14728222.2021.1954162 34236924
Bui TM, Yalom LK, Sumagin R. Tumor-associated neutrophils: orchestrating cancer pathobiology and therapeutic resistance. Expert Opin Ther Targets. 2021;25:573–83.34236924
20. Lad BM, Beniwal AS, Jain S, Shukla P, Jung J, Shah SS, Yagnik G, Babikir H, Nguyen AT, Gill S et al. Glioblastoma induces the recruitment and differentiation of hybrid neutrophils from skull bone marrow. bioRxiv 2023.
21. Singhal S Bhojnagarwala PS O’Brien S Moon EK Garfall AL Rao AS Quatromoni JG Stephen TL Litzky L Deshpande C Origin and role of a subset of Tumor-Associated neutrophils with Antigen-presenting cell features in early-stage human lung Cancer Cancer Cell 2016 30 120 35 10.1016/j.ccell.2016.06.001 27374224
Singhal S, Bhojnagarwala PS, O’Brien S, Moon EK, Garfall AL, Rao AS, Quatromoni JG, Stephen TL, Litzky L, Deshpande C, et al. Origin and role of a subset of Tumor-Associated neutrophils with Antigen-presenting cell features in early-stage human lung Cancer. Cancer Cell. 2016;30:120–35.27374224
22. Kolaczkowska E Kubes P Neutrophil recruitment and function in health and inflammation Nat Rev Immunol 2013 13 159 75 10.1038/nri3399 23435331
Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13:159–75.23435331
23. Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the Immune System and diseases. Int J Mol Sci 2022, 23.
24. Gomes Dos Santos A, de Carvalho RF, de Morais ANLR, Silva TM, Baylão VMR, Azevedo M, de Oliveira AJM. Role of neutrophil-lymphocyte ratio as a predictive factor of glioma t umor grade: A systematic review. Critical reviews in oncology/hematology 2021, 163:103372.
25. Stadtmann A Zarbock A CXCR2: from bench to Bedside Front Immunol 2012 3 263 10.3389/fimmu.2012.00263 22936934
Stadtmann A, Zarbock A. CXCR2: from bench to Bedside. Front Immunol. 2012;3:263.22936934
26. Wang G Wang J Niu C Zhao Y Wu P Neutrophils: new critical regulators of Glioma Front Immunol 2022 13 927233 10.3389/fimmu.2022.927233 35860278
Wang G, Wang J, Niu C, Zhao Y, Wu P. Neutrophils: new critical regulators of Glioma. Front Immunol. 2022;13:927233.35860278
27. Yang L Liu Z Wu R Yao Q Gu Z Liu M Correlation of C-X-C chemokine receptor 2 upregulation with poor prognosis and recurrence in human glioma Onco Targets Ther 2015 8 3203 9 26586954
Yang L, Liu Z, Wu R, Yao Q, Gu Z, Liu M. Correlation of C-X-C chemokine receptor 2 upregulation with poor prognosis and recurrence in human glioma. Onco Targets Ther. 2015;8:3203–9.26586954
28. Chen N, Alieva M, van der Most T, Klazen JAZ, Vollmann-Zwerenz A, Hau P, Vrisekoop N. Neutrophils promote Glioblastoma Tumor Cell Migration after Biopsy. Cells 2022, 11.
29. Köhler A De Filippo K Hasenberg M van den Brandt C Nye E Hosking MP Lane TE Männ L Ransohoff RM Hauser AE G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands Blood 2011 117 4349 57 10.1182/blood-2010-09-308387 21224471
Köhler A, De Filippo K, Hasenberg M, van den Brandt C, Nye E, Hosking MP, Lane TE, Männ L, Ransohoff RM, Hauser AE, et al. G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood. 2011;117:4349–57.21224471
30. Kasahara T Mukaida N Yamashita K Yagisawa H Akahoshi T Matsushima K IL-1 and TNF-alpha induction of IL-8 and monocyte chemotactic and activating factor (MCAF) mRNA expression in a human astrocytoma cell line Immunology 1991 74 60 7 1937574
Kasahara T, Mukaida N, Yamashita K, Yagisawa H, Akahoshi T, Matsushima K. IL-1 and TNF-alpha induction of IL-8 and monocyte chemotactic and activating factor (MCAF) mRNA expression in a human astrocytoma cell line. Immunology. 1991;74:60–7.1937574
31. Griffin BD Moynagh PN Persistent interleukin-1beta signaling causes long term activation of NFkappaB in a promoter-specific manner in human glial cells J Biol Chem 2006 281 10316 26 10.1074/jbc.M509973200 16455661
Griffin BD, Moynagh PN. Persistent interleukin-1beta signaling causes long term activation of NFkappaB in a promoter-specific manner in human glial cells. J Biol Chem. 2006;281:10316–26.16455661
32. Tarassishin L Lim J Weatherly DB Angeletti RH Lee SC Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression J Proteom 2014 99 152 68 10.1016/j.jprot.2014.01.024
Tarassishin L, Lim J, Weatherly DB, Angeletti RH, Lee SC. Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression. J Proteom. 2014;99:152–68.
33. Hor WS Huang WL Lin YS Yang BC Cross-talk between tumor cells and neutrophils through the Fas (APO-1, CD95)/FasL system: human glioma cells enhance cell viability and stimulate cytokine production in neutrophils J Leukoc Biol 2003 73 363 8 10.1189/jlb.0702375 12629150
Hor WS, Huang WL, Lin YS, Yang BC. Cross-talk between tumor cells and neutrophils through the Fas (APO-1, CD95)/FasL system: human glioma cells enhance cell viability and stimulate cytokine production in neutrophils. J Leukoc Biol. 2003;73:363–8.12629150
34. Zha C Meng X Li L Mi S Qian D Li Z Wu P Hu S Zhao S Cai J Liu Y Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis Cancer Biol Med 2020 17 154 68 10.20892/j.issn.2095-3941.2019.0353 32296583
Zha C, Meng X, Li L, Mi S, Qian D, Li Z, Wu P, Hu S, Zhao S, Cai J, Liu Y. Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis. Cancer Biol Med. 2020;17:154–68.32296583
35. Powell D Lou M Barros Becker F Huttenlocher A Cxcr1 mediates recruitment of neutrophils and supports proliferation of tumor-initiating astrocytes in vivo Sci Rep 2018 8 13285 10.1038/s41598-018-31675-0 30185911
Powell D, Lou M, Barros Becker F, Huttenlocher A. Cxcr1 mediates recruitment of neutrophils and supports proliferation of tumor-initiating astrocytes in vivo. Sci Rep. 2018;8:13285.30185911
36. Wang T, Cao L, Dong X, Wu F, De W, Huang L, Wan Q. LINC01116 promotes tumor proliferation and neutrophil recruitment via DDX5-mediated regulation of IL-1β in glioma cell. Cell Death Dis 2020, 11.
37. Lee SY Kim JK Jeon HY Ham SW Kim H CD133 regulates IL-1beta signaling and Neutrophil Recruitment in Glioblastoma Mol Cells 2017 40 515 22 10.14348/molcells.2017.0089 28736425
Lee SY, Kim JK, Jeon HY, Ham SW, Kim H. CD133 regulates IL-1beta signaling and Neutrophil Recruitment in Glioblastoma. Mol Cells. 2017;40:515–22.28736425
38. Fridlender ZG Sun J Kim S Kapoor V Cheng G Ling L Worthen GS Albelda SM Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN Cancer Cell 2009 16 183 94 10.1016/j.ccr.2009.06.017 19732719
Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell. 2009;16:183–94.19732719
39. Zhu S Yi M Wu Y Dong B Wu K Roles of tumor-associated macrophages in tumor progression: implicatio ns on therapeutic strategies Experimental Hematol Oncol 2021 10 60 10.1186/s40164-021-00252-z
Zhu S, Yi M, Wu Y, Dong B, Wu K. Roles of tumor-associated macrophages in tumor progression: implicatio ns on therapeutic strategies. Experimental Hematol Oncol. 2021;10:60.
40. Kim J, Bae JS. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm 2016, 2016:6058147.
41. Mishalian I Bayuh R Levy L Zolotarov L Michaeli J Fridlender ZG Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression Cancer Immunol Immunother 2013 62 1745 56 10.1007/s00262-013-1476-9 24092389
Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother. 2013;62:1745–56.24092389
42. Ng MSF Kwok I Tan L Shi C Cerezo-Wallis D Tan Y Leong K Calvo GF Yang K Zhang Y Deterministic reprogramming of neutrophils within tumors Science 2024 383 eadf6493 10.1126/science.adf6493 38207030
Ng MSF, Kwok I, Tan L, Shi C, Cerezo-Wallis D, Tan Y, Leong K, Calvo GF, Yang K, Zhang Y, et al. Deterministic reprogramming of neutrophils within tumors. Science. 2024;383:eadf6493.38207030
43. Ng MSF Tan L Wang Q Mackay CR Ng LG Neutrophils in cancer-unresolved questions Sci China Life Sci 2021 64 1829 41 10.1007/s11427-020-1853-4 33661490
Ng MSF, Tan L, Wang Q, Mackay CR, Ng LG. Neutrophils in cancer-unresolved questions. Sci China Life Sci. 2021;64:1829–41.33661490
44. Sathornsumetee S, Rich JN. Chap. 18 - Molecularly targeted therapy in neuro-oncology. In Handbook of Clinical Neurology. Volume 104. Edited by Aminoff MJ, Boller F, Swaab DF: Elsevier; 2012: 255–278.
45. Chen R Smith-Cohn M Cohen AL Colman H Glioma subclassifications and their clinical significance Neurotherapeutics 2017 14 284 97 10.1007/s13311-017-0519-x 28281173
Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14:284–97.28281173
46. Han S Liu Y Cai SJ Qian M Ding J Larion M Gilbert MR Yang C IDH mutation in glioma: molecular mechanisms and potential therapeutic targets Br J Cancer 2020 122 1580 9 10.1038/s41416-020-0814-x 32291392
Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122:1580–9.32291392
47. Andzinski L Kasnitz N Stahnke S Wu CF Gereke M von Kockritz-Blickwede M Schilling B Brandau S Weiss S Jablonska J Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human Int J Cancer 2016 138 1982 93 10.1002/ijc.29945 26619320
Andzinski L, Kasnitz N, Stahnke S, Wu CF, Gereke M, von Kockritz-Blickwede M, Schilling B, Brandau S, Weiss S, Jablonska J. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. 2016;138:1982–93.26619320
48. Demkow U. Neutrophil Extracellular traps (NETs) in Cancer Invasion, Evasion and Metastasis. Cancers (Basel) 2021, 13.
49. Cristinziano L Modestino L Antonelli A Marone G Simon HU Varricchi G Galdiero MR Neutrophil extracellular traps in cancer Semin Cancer Biol 2022 79 91 104 10.1016/j.semcancer.2021.07.011 34280576
Cristinziano L, Modestino L, Antonelli A, Marone G, Simon HU, Varricchi G, Galdiero MR. Neutrophil extracellular traps in cancer. Semin Cancer Biol. 2022;79:91–104.34280576
50. Albrengues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, Upadhyay P, Uyeminami DL, Pommier A, Kuttner V et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 2018, 361.
51. Iwatsuki K Kumara E Yoshimine T Nakagawa H Sato M Hayakawa T Elastase expression by infiltrating neutrophils in gliomas Neurol Res 2000 22 465 8 10.1080/01616412.2000.11740701 10935217
Iwatsuki K, Kumara E, Yoshimine T, Nakagawa H, Sato M, Hayakawa T. Elastase expression by infiltrating neutrophils in gliomas. Neurol Res. 2000;22:465–8.10935217
52. Crocker J Jenkins R Burnett D Immunohistochemical demonstration of leucocyte elastase in human tissues J Clin Pathol 1984 37 1114 8 10.1136/jcp.37.10.1114 6386890
Crocker J, Jenkins R, Burnett D. Immunohistochemical demonstration of leucocyte elastase in human tissues. J Clin Pathol. 1984;37:1114–8.6386890
53. Xue Q Cao L Chen XY Zhao J Gao L Li SZ Fei Z High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates Oncol Lett 2017 13 1325 30 10.3892/ol.2017.5567 28454256
Xue Q, Cao L, Chen XY, Zhao J, Gao L, Li SZ, Fei Z. High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates. Oncol Lett. 2017;13:1325–30.28454256
54. Rubenich DS de Souza PO Omizzollo N Aubin MR Basso PJ Silva LM da Silva EM Teixeira FC Gentil GFS Domagalski JL Tumor-neutrophil crosstalk promotes in vitro and in vivo glioblastoma progression Front Immunol 2023 14 1183465 10.3389/fimmu.2023.1183465 37292196
Rubenich DS, de Souza PO, Omizzollo N, Aubin MR, Basso PJ, Silva LM, da Silva EM, Teixeira FC, Gentil GFS, Domagalski JL, et al. Tumor-neutrophil crosstalk promotes in vitro and in vivo glioblastoma progression. Front Immunol. 2023;14:1183465.37292196
55. Houghton AM Rzymkiewicz DM Ji H Gregory AD Egea EE Metz HE Stolz DB Land SR Marconcini LA Kliment CR Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth Nat Med 2010 16 219 23 10.1038/nm.2084 20081861
Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010;16:219–23.20081861
56. Hattar K Franz K Ludwig M Sibelius U Wilhelm J Lohmeyer J Savai R Subtil FS Dahlem G Eul B Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis Cancer Immunol Immunother 2014 63 1297 306 10.1007/s00262-014-1606-z 25186613
Hattar K, Franz K, Ludwig M, Sibelius U, Wilhelm J, Lohmeyer J, Savai R, Subtil FS, Dahlem G, Eul B, et al. Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis. Cancer Immunol Immunother. 2014;63:1297–306.25186613
57. Zhou SL Yin D Hu ZQ Luo CB Zhou ZJ Xin HY Yang XR Shi YH Wang Z Huang XW A positive Feedback Loop between Cancer Stem-Like cells and Tumor-Associated neutrophils Controls Hepatocellular Carcinoma Progression Hepatology 2019 70 1214 30 10.1002/hep.30630 30933361
Zhou SL, Yin D, Hu ZQ, Luo CB, Zhou ZJ, Xin HY, Yang XR, Shi YH, Wang Z, Huang XW, et al. A positive Feedback Loop between Cancer Stem-Like cells and Tumor-Associated neutrophils Controls Hepatocellular Carcinoma Progression. Hepatology. 2019;70:1214–30.30933361
58. Yee PP Wei Y Kim SY Lu T Chih SY Lawson C Tang M Liu Z Anderson B Thamburaj K Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression Nat Commun 2020 11 5424 10.1038/s41467-020-19193-y 33110073
Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, Tang M, Liu Z, Anderson B, Thamburaj K, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11:5424.33110073
59. Yao L Sheng X Dong X Zhou W Li Y Ma X Song Y Dai H Du Y Neutrophil extracellular traps mediate TLR9/Merlin axis to resist ferroptosis and promote triple negative breast cancer progression Apoptosis 2023 28 1484 95 10.1007/s10495-023-01866-w 37368176
Yao L, Sheng X, Dong X, Zhou W, Li Y, Ma X, Song Y, Dai H, Du Y. Neutrophil extracellular traps mediate TLR9/Merlin axis to resist ferroptosis and promote triple negative breast cancer progression. Apoptosis. 2023;28:1484–95.37368176
60. Onishi M Ichikawa T Kurozumi K Date I Angiogenesis and invasion in glioma Brain Tumor Pathol 2011 28 13 24 10.1007/s10014-010-0007-z 21221826
Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol. 2011;28:13–24.21221826
61. Tazzyman S Lewis CE Murdoch C Neutrophils: key mediators of tumour angiogenesis Int J Exp Pathol 2009 90 222 31 10.1111/j.1365-2613.2009.00641.x 19563607
Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol. 2009;90:222–31.19563607
62. Simons M Gordon E Claesson-Welsh L Mechanisms and regulation of endothelial VEGF receptor signalling Nat Rev Mol Cell Biol 2016 17 611 25 10.1038/nrm.2016.87 27461391
Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17:611–25.27461391
63. Ardi VC Kupriyanova TA Deryugina EI Quigley JP Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis Proc Natl Acad Sci U S A 2007 104 20262 7 10.1073/pnas.0706438104 18077379
Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A. 2007;104:20262–7.18077379
64. Masure S Proost P Van Damme J Opdenakker G Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8 Eur J Biochem 1991 198 391 8 10.1111/j.1432-1033.1991.tb16027.x 1645657
Masure S, Proost P, Van Damme J, Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur J Biochem. 1991;198:391–8.1645657
65. Van den Steen PE Proost P Wuyts A Van Damme J Opdenakker G Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact Blood 2000 96 2673 81 10.1182/blood.V96.8.2673 11023497
Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood. 2000;96:2673–81.11023497
66. Cassatella MA Neutrophil-derived proteins: selling cytokines by the pound Adv Immunol 1999 73 369 509 10.1016/S0065-2776(08)60791-9 10399011
Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. Adv Immunol. 1999;73:369–509.10399011
67. Shojaei F Wu X Zhong C Yu L Liang X-H Yao J Blanchard D Bais C Peale FV van Bruggen N Bv8 regulates myeloid-cell-dependent tumour angiogenesis Nature 2007 450 825 31 10.1038/nature06348 18064003
Shojaei F, Wu X, Zhong C, Yu L, Liang X-H, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007;450:825–31.18064003
68. LeCouter J Ferrara N EG-VEGF and Bv8. A novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function Trends Cardiovasc Med 2003 13 276 82 10.1016/S1050-1738(03)00110-5 14522467
LeCouter J, Ferrara N. EG-VEGF and Bv8. A novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function. Trends Cardiovasc Med. 2003;13:276–82.14522467
69. Xin H Lu R Lee H Zhang W Zhang C Deng J Liu Y Shen S Wagner K-U Forman S G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protei n form a feed-forward loop in both normal and malignant myeloid cells J Biol Chem 2013 288 13842 9 10.1074/jbc.M113.450049 23548897
Xin H, Lu R, Lee H, Zhang W, Zhang C, Deng J, Liu Y, Shen S, Wagner K-U, Forman S, et al. G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protei n form a feed-forward loop in both normal and malignant myeloid cells. J Biol Chem. 2013;288:13842–9.23548897
70. Qu X Zhuang G Yu L Meng G Ferrara N Induction of Bv8 expression by granulocyte colony-stimulating factor i n CD11b + Gr1 + cells: key role of Stat3 signaling J Biol Chem 2012 287 19574 84 10.1074/jbc.M111.326801 22528488
Qu X, Zhuang G, Yu L, Meng G, Ferrara N. Induction of Bv8 expression by granulocyte colony-stimulating factor i n CD11b + Gr1 + cells: key role of Stat3 signaling. J Biol Chem. 2012;287:19574–84.22528488
71. Curtis VF Wang H Yang P McLendon RE Li X Zhou QY Wang XF A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer PLoS ONE 2013 8 e54916 10.1371/journal.pone.0054916 23372791
Curtis VF, Wang H, Yang P, McLendon RE, Li X, Zhou QY, Wang XF. A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. PLoS ONE. 2013;8:e54916.23372791
72. Bui TM, Yalom LK, Ning E, Urbanczyk JM, Ren X, Herrnreiter CJ, Disario JA, Wray B, Schipma MJ, Velichko YS et al. Tissue-specific reprogramming leads to angiogenic neutrophil specialization and tumor vascularization in colorectal cancer. J Clin Invest 2024, 134.
73. Dai J Peng L Fan K Wang H Wei R Ji G Cai J Lu B Li B Zhang D Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells Oncogene 2009 28 3412 22 10.1038/onc.2009.189 19597469
Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, et al. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene. 2009;28:3412–22.19597469
74. Han KY Chang JH Lee H Azar DT Proangiogenic interactions of vascular endothelial MMP14 with VEGF receptor 1 in VEGFA-Mediated corneal angiogenesis Invest Ophthalmol Vis Sci 2016 57 3313 22 10.1167/iovs.16-19420 27327585
Han KY, Chang JH, Lee H, Azar DT. Proangiogenic interactions of vascular endothelial MMP14 with VEGF receptor 1 in VEGFA-Mediated corneal angiogenesis. Invest Ophthalmol Vis Sci. 2016;57:3313–22.27327585
75. Blaheta RA Powerski M Hudak L Juengel E Jonas D von Knethen A Doerr HW Cinatl J Jr Tumor-endothelium cross talk blocks recruitment of neutrophils to endothelial cells: a novel mechanism of endothelial cell anergy Neoplasia 2009 11 1054 63 10.1593/neo.09762 19794964
Blaheta RA, Powerski M, Hudak L, Juengel E, Jonas D, von Knethen A, Doerr HW, Cinatl J Jr. Tumor-endothelium cross talk blocks recruitment of neutrophils to endothelial cells: a novel mechanism of endothelial cell anergy. Neoplasia. 2009;11:1054–63.19794964
76. Lee E Yong RL Paddison P Zhu J Comparison of glioblastoma (GBM) molecular classification methods Semin Cancer Biol 2018 53 201 11 10.1016/j.semcancer.2018.07.006 30031763
Lee E, Yong RL, Paddison P, Zhu J. Comparison of glioblastoma (GBM) molecular classification methods. Semin Cancer Biol. 2018;53:201–11.30031763
77. Lai Y Lu X Liao Y Ouyang P Wang H Zhang X Huang G Qi S Li Y Crosstalk between glioblastoma and tumor microenvironment drives proneural-mesenchymal transition through ligand-receptor interactions Genes Dis 2023 11 874 89 10.1016/j.gendis.2023.05.025 37692522
Lai Y, Lu X, Liao Y, Ouyang P, Wang H, Zhang X, Huang G, Qi S, Li Y. Crosstalk between glioblastoma and tumor microenvironment drives proneural-mesenchymal transition through ligand-receptor interactions. Genes Dis. 2023;11:874–89.37692522
78. Verhaak RG Hoadley KA Purdom E Wang V Qi Y Wilkerson MD Miller CR Ding L Golub T Mesirov JP Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 2010 17 98 110 10.1016/j.ccr.2009.12.020 20129251
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.20129251
79. Fedele M, Cerchia L, Pegoraro S, Sgarra R, Manfioletti G. Proneural-mesenchymal transition: phenotypic plasticity to acquire Multitherapy Resistance in Glioblastoma. Int J Mol Sci 2019, 20.
80. Hara T Chanoch-Myers R Mathewson ND Myskiw C Atta L Bussema L Eichhorn SW Greenwald AC Kinker GS Rodman C Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma Cancer Cell 2021 39 779 e792711 10.1016/j.ccell.2021.05.002 34087162
Hara T, Chanoch-Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L, Eichhorn SW, Greenwald AC, Kinker GS, Rodman C, et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell. 2021;39:779–e792711.34087162
81. Bresnick AR Weber DJ Zimmer DB S100 proteins in cancer Nat Rev Cancer 2015 15 96 109 10.1038/nrc3893 25614008
Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer. 2015;15:96–109.25614008
82. Fei F Qu J Zhang M Li Y Zhang S S100A4 in cancer progression and metastasis: a systematic review Oncotarget 2017 8 73219 39 10.18632/oncotarget.18016 29069865
Fei F, Qu J, Zhang M, Li Y, Zhang S. S100A4 in cancer progression and metastasis: a systematic review. Oncotarget. 2017;8:73219–39.29069865
83. Liang J Piao Y Holmes L Fuller GN Henry V Tiao N de Groot JF Neutrophils promote the malignant glioma phenotype through S100A4 Clin Cancer Res 2014 20 187 98 10.1158/1078-0432.CCR-13-1279 24240114
Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2014;20:187–98.24240114
84. Chow KH Park HJ George J Yamamoto K Gallup AD Graber JH Chen Y Jiang W Steindler DA Neilson EG S100A4 is a Biomarker and Regulator of Glioma Stem cells that is critical for mesenchymal transition in Glioblastoma Cancer Res 2017 77 5360 73 10.1158/0008-5472.CAN-17-1294 28807938
Chow KH, Park HJ, George J, Yamamoto K, Gallup AD, Graber JH, Chen Y, Jiang W, Steindler DA, Neilson EG, et al. S100A4 is a Biomarker and Regulator of Glioma Stem cells that is critical for mesenchymal transition in Glioblastoma. Cancer Res. 2017;77:5360–73.28807938
85. Chen Z Soni N Pinero G Giotti B Eddins DJ Lindblad KE Ross JL Puigdelloses Vallcorba M Joshi T Angione A Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma Nat Commun 2023 14 1839 10.1038/s41467-023-37361-8 37012245
Chen Z, Soni N, Pinero G, Giotti B, Eddins DJ, Lindblad KE, Ross JL, Puigdelloses Vallcorba M, Joshi T, Angione A, et al. Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma. Nat Commun. 2023;14:1839.37012245
86. SenGupta S Subramanian BC Parent CA Getting TANned: how the tumor microenvironment drives neutrophil recruitment J Leukoc Biol 2019 105 449 62 10.1002/JLB.3RI0718-282R 30549315
SenGupta S, Subramanian BC, Parent CA. Getting TANned: how the tumor microenvironment drives neutrophil recruitment. J Leukoc Biol. 2019;105:449–62.30549315
87. Kaur B Khwaja FW Severson EA Matheny SL Brat DJ Van Meir EG Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis Neuro Oncol 2005 7 134 53 10.1215/S1152851704001115 15831232
Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol. 2005;7:134–53.15831232
88. Liu D, Zhu HT, Cheng LD, Li R, Ma XY, Wang J, Wang JW, Zhang SJ, Li YJ, Shu K et al. Hypoxia-induced galectin-8 maintains stemness in glioma stem cells via autophagy regulation. Neuro-Oncology 2023.
89. Görlach A Bonello S The cross-talk between NF-kappaB and HIF-1: further evidence for a sig nificant liaison Biochem J 2008 412 e17 19 10.1042/BJ20080920 18498249
Görlach A, Bonello S. The cross-talk between NF-kappaB and HIF-1: further evidence for a sig nificant liaison. Biochem J. 2008;412:e17–19.18498249
90. Jin MZ Jin WL The updated landscape of tumor microenvironment and drug repurposing Signal Transduct Target Ther 2020 5 166 10.1038/s41392-020-00280-x 32843638
Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020;5:166.32843638
91. Eales KL Hollinshead KER Tennant DA Hypoxia and metabolic adaptation of cancer cells Oncogenesis 2016 5 e190 10.1038/oncsis.2015.50 26807645
Eales KL, Hollinshead KER, Tennant DA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis. 2016;5:e190.26807645
92. Xu L Xie K Mukaida N Matsushima K Fidler IJ Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells Cancer Res 1999 59 5822 9 10582705
Xu L, Xie K, Mukaida N, Matsushima K, Fidler IJ. Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res. 1999;59:5822–9.10582705
93. Beaumont JEJ, Beelen NA, Wieten L, Rouschop KMA. The Immunomodulatory Role of Hypoxic Tumor-Derived Extracellular vesicles. Cancers (Basel) 2022, 14.
94. Baggiolini M Walz A Kunkel SL Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils J Clin Invest 1989 84 1045 9 10.1172/JCI114265 2677047
Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989;84:1045–9.2677047
95. Murata K Yoshitomi H Furu M Ishikawa M Shibuya H Ito H Matsuda S MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK Arthritis Rheumatol 2014 66 549 59 10.1002/art.38269 24574214
Murata K, Yoshitomi H, Furu M, Ishikawa M, Shibuya H, Ito H, Matsuda S. MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK. Arthritis Rheumatol. 2014;66:549–59.24574214
96. Triner D Xue X Schwartz AJ Jung I Colacino JA Shah YM Epithelial hypoxia-inducible factor 2α facilitates the Progression of Colon Tumors through recruiting neutrophils Mol Cell Biol 2017 37 e00481 00416 10.1128/MCB.00481-16 27956697
Triner D, Xue X, Schwartz AJ, Jung I, Colacino JA, Shah YM. Epithelial hypoxia-inducible factor 2α facilitates the Progression of Colon Tumors through recruiting neutrophils. Mol Cell Biol. 2017;37:e00481–00416.27956697
97. Tsai HC Tong ZJ Hwang TL Wei KC Chen PY Huang CY Chen KT Lin YJ Cheng HW Wang HT Acrolein produced by glioma cells under hypoxia inhibits neutrophil AKT activity and suppresses anti-tumoral activities Free Radic Biol Med 2023 207 17 28 10.1016/j.freeradbiomed.2023.06.027 37414347
Tsai HC, Tong ZJ, Hwang TL, Wei KC, Chen PY, Huang CY, Chen KT, Lin YJ, Cheng HW, Wang HT. Acrolein produced by glioma cells under hypoxia inhibits neutrophil AKT activity and suppresses anti-tumoral activities. Free Radic Biol Med. 2023;207:17–28.37414347
98. Broekman ML Maas SLN Abels ER Mempel TR Krichevsky AM Breakefield XO Multidimensional communication in the microenvirons of glioblastoma Nat Rev Neurol 2018 14 482 95 10.1038/s41582-018-0025-8 29985475
Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO. Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol. 2018;14:482–95.29985475
99. Grabowski MM Sankey EW Ryan KJ Chongsathidkiet P Lorrey SJ Wilkinson DS Fecci PE Immune suppression in gliomas J Neurooncol 2021 151 3 12 10.1007/s11060-020-03483-y 32542437
Grabowski MM, Sankey EW, Ryan KJ, Chongsathidkiet P, Lorrey SJ, Wilkinson DS, Fecci PE. Immune suppression in gliomas. J Neurooncol. 2021;151:3–12.32542437
100. Alberghina C Torrisi F D’Aprile S Longhitano L Giallongo S Scandura G Mannino G Mele S Sabini MG Cammarata FP Microglia and glioblastoma heterocellular interplay sustains tumour gr owth and proliferation as an off-target effect of radiotherapy Cell Prolif 2024 57 e13606 10.1111/cpr.13606 38454614
Alberghina C, Torrisi F, D’Aprile S, Longhitano L, Giallongo S, Scandura G, Mannino G, Mele S, Sabini MG, Cammarata FP, et al. Microglia and glioblastoma heterocellular interplay sustains tumour gr owth and proliferation as an off-target effect of radiotherapy. Cell Prolif. 2024;57:e13606.38454614
101. Khan F, Pang L, Dunterman M, Lesniak MS, Heimberger AB, Chen P. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Invest 2023, 133.
102. Zhou Z, Wang P, Sun R, Li J, Hu Z, Xin H, Luo C, Zhou J, Fan J, Zhou S. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. J Immunother Cancer 2021, 9.
103. Hu J Zhang L Xia H Yan Y Zhu X Sun F Sun L Li S Li D Wang J Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing Genome Med 2023 15 14 10.1186/s13073-023-01164-9 36869384
Hu J, Zhang L, Xia H, Yan Y, Zhu X, Sun F, Sun L, Li S, Li D, Wang J, et al. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 2023;15:14.36869384
104. Ponzetta A Carriero R Carnevale S Barbagallo M Molgora M Perucchini C Magrini E Gianni F Kunderfranco P Polentarutti N Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors Cell 2019 178 346 e360324 10.1016/j.cell.2019.05.047 31257026
Ponzetta A, Carriero R, Carnevale S, Barbagallo M, Molgora M, Perucchini C, Magrini E, Gianni F, Kunderfranco P, Polentarutti N, et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell. 2019;178:346–e360324.31257026
105. Basheer AS, Abas F, Othman I, Naidu R. Role of Inflammatory mediators, macrophages, and neutrophils in Glioma Maintenance and progression: mechanistic understanding and potential therapeutic applications. Cancers (Basel) 2021, 13.
106. Locarno CV Simonelli M Carenza C Capucetti A Stanzani E Lorenzi E Persico P Della Bella S Passoni L Mavilio D Role of myeloid cells in the immunosuppressive microenvironment in gliomas Immunobiology 2020 225 151853 10.1016/j.imbio.2019.10.002 31703822
Locarno CV, Simonelli M, Carenza C, Capucetti A, Stanzani E, Lorenzi E, Persico P, Della Bella S, Passoni L, Mavilio D, et al. Role of myeloid cells in the immunosuppressive microenvironment in gliomas. Immunobiology. 2020;225:151853.31703822
107. Jaillon S Ponzetta A Di Mitri D Santoni A Bonecchi R Mantovani A Neutrophil diversity and plasticity in tumour progression and therapy Nat Rev Cancer 2020 20 485 503 10.1038/s41568-020-0281-y 32694624
Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20:485–503.32694624
108. Sippel TR White J Nag K Tsvankin V Klaassen M Kleinschmidt-DeMasters BK Waziri A Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I Clin Cancer Res 2011 17 6992 7002 10.1158/1078-0432.CCR-11-1107 21948231
Sippel TR, White J, Nag K, Tsvankin V, Klaassen M, Kleinschmidt-DeMasters BK, Waziri A. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res. 2011;17:6992–7002.21948231
109. Han Y Liu D Li L PD-1/PD-L1 pathway: current researches in cancer Am J Cancer Res 2020 10 727 42 32266087
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727–42.32266087
110. Wang X Guo G Guan H Yu Y Lu J Yu J Challenges and potential of PD-1/PD-L1 checkpoint blockade immunothera py for glioblastoma J Experimental Clin cancer Research: CR 2019 38 87 10.1186/s13046-019-1085-3
Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunothera py for glioblastoma. J Experimental Clin cancer Research: CR. 2019;38:87.
111. Maas RR Soukup K Fournier N Massara M Galland S Kornete M Wischnewski V Lourenco J Croci D Álvarez-Prado ÁF The local microenvironment drives activation of neutrophils in human b rain tumors Cell 2023 186 4546 e45664527 10.1016/j.cell.2023.08.043 37769657
Maas RR, Soukup K, Fournier N, Massara M, Galland S, Kornete M, Wischnewski V, Lourenco J, Croci D, Álvarez-Prado ÁF, et al. The local microenvironment drives activation of neutrophils in human b rain tumors. Cell. 2023;186:4546–e45664527.37769657
112. Dubinski D Wolfer J Hasselblatt M Schneider-Hohendorf T Bogdahn U Stummer W Wiendl H Grauer OM CD4 + T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients Neuro Oncol 2016 18 807 18 10.1093/neuonc/nov280 26578623
Dubinski D, Wolfer J, Hasselblatt M, Schneider-Hohendorf T, Bogdahn U, Stummer W, Wiendl H, Grauer OM. CD4 + T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol. 2016;18:807–18.26578623
113. Fujita M Scheurer ME Decker SA McDonald HA Kohanbash G Kastenhuber ER Kato H Bondy ML Ohlfest JR Okada H Role of type 1 IFNs in antiglioma immunosurveillance–using mouse studies to guide examination of novel prognostic markers in humans Clin Cancer Res 2010 16 3409 19 10.1158/1078-0432.CCR-10-0644 20472682
Fujita M, Scheurer ME, Decker SA, McDonald HA, Kohanbash G, Kastenhuber ER, Kato H, Bondy ML, Ohlfest JR, Okada H. Role of type 1 IFNs in antiglioma immunosurveillance–using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res. 2010;16:3409–19.20472682
114. Kim R Hashimoto A Markosyan N Tyurin VA Tyurina YY Kar G Fu S Sehgal M Garcia-Gerique L Kossenkov A Ferroptosis of tumour neutrophils causes immune suppression in cancer Nature 2022 612 338 46 10.1038/s41586-022-05443-0 36385526
Kim R, Hashimoto A, Markosyan N, Tyurin VA, Tyurina YY, Kar G, Fu S, Sehgal M, Garcia-Gerique L, Kossenkov A, et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature. 2022;612:338–46.36385526
115. Khan S, Mittal S, McGee K, Alfaro-Munoz KD, Majd N, Balasubramaniyan V, de Groot JF. Role of neutrophils and myeloid-derived suppressor cells in Glioma Progression and Treatment Resistance. Int J Mol Sci 2020, 21.
116. Jeon HY Ham SW Kim JK Jin X Lee SY Shin YJ Choi CY Sa JK Kim SH Chun T Ly6G(+) inflammatory cells enable the conversion of cancer cells to cancer stem cells in an irradiated glioblastoma model Cell Death Differ 2019 26 2139 56 10.1038/s41418-019-0282-0 30804471
Jeon HY, Ham SW, Kim JK, Jin X, Lee SY, Shin YJ, Choi CY, Sa JK, Kim SH, Chun T, et al. Ly6G(+) inflammatory cells enable the conversion of cancer cells to cancer stem cells in an irradiated glioblastoma model. Cell Death Differ. 2019;26:2139–56.30804471
117. Ancey PB Contat C Boivin G Sabatino S Pascual J Zangger N Perentes JY Peters S Abel ED Kirsch DG GLUT1 expression in Tumor-Associated neutrophils promotes Lung Cancer Growth and Resistance to Radiotherapy Cancer Res 2021 81 2345 57 10.1158/0008-5472.CAN-20-2870 33753374
Ancey PB, Contat C, Boivin G, Sabatino S, Pascual J, Zangger N, Perentes JY, Peters S, Abel ED, Kirsch DG, et al. GLUT1 expression in Tumor-Associated neutrophils promotes Lung Cancer Growth and Resistance to Radiotherapy. Cancer Res. 2021;81:2345–57.33753374
118. Nakada M Kita D Watanabe T Hayashi Y Hamada J Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma Brain Tumor Pathol 2014 31 198 207 10.1007/s10014-013-0174-9 24399202
Nakada M, Kita D, Watanabe T, Hayashi Y, Hamada J. Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma. Brain Tumor Pathol. 2014;31:198–207.24399202
119. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mo use model of multistage carcinogenesis. Proceedings of the National Academy of Sciences of the United States o f America 2006, 103:12493–12498.
120. Finke J Ko J Rini B Rayman P Ireland J Cohen P MDSC as a mechanism of tumor escape from sunitinib mediated anti-angio genic therapy Int Immunopharmacol 2011 11 856 61 10.1016/j.intimp.2011.01.030 21315783
Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angio genic therapy. Int Immunopharmacol. 2011;11:856–61.21315783
121. Itatani Y, Yamamoto T, Zhong C, Molinolo AA, Ruppel J, Hegde P, Taketo MM, Ferrara N. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proceedings of the National Academy of Sciences of the United States o f America 2020, 117:21598–21608.
122. Piao Y Liang J Holmes L Henry V Sulman E de Groot JF Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition Clin cancer Research: Official J Am Associa Tion Cancer Res 2013 19 4392 403 10.1158/1078-0432.CCR-12-1557
Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin cancer Research: Official J Am Associa Tion Cancer Res. 2013;19:4392–403.
123. Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AM. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest 2023, 133.
124. Torrisi F, D’Aprile S, Denaro S, Pavone AM, Alberghina C, Zappalà A, Giuffrida R, Salvatorelli L, Broggi G, Magro GG et al. Epigenetics and metabolism reprogramming interplay into Glioblastoma: Novel insights on immunosuppressive mechanisms. Antioxid (Basel) 2023, 12.
125. Morad G Helmink BA Sharma P Wargo JA Hallmarks of response, resistance, and toxicity to immune checkpoint blockade Cell 2021 184 5309 37 10.1016/j.cell.2021.09.020 34624224
Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309–37.34624224
126. Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promo ter. Neuro-oncology 2022, 24:1935–1949.
127. Chinot OL Wick W Mason W Henriksson R Saran F Nishikawa R Carpentier AF Hoang-Xuan K Kavan P Cernea D Bevacizumab plus radiotherapy-temozolomide for newly diagnosed Gliobla Stoma N Engl J Med 2014 370 709 22 10.1056/NEJMoa1308345 24552318
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed Gliobla Stoma. N Engl J Med. 2014;370:709–22.24552318
128. Gilbert MR Dignam JJ Armstrong TS Wefel JS Blumenthal DT Vogelbaum MA Colman H Chakravarti A Pugh S Won M A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 2014 370 699 708 10.1056/NEJMoa1308573 24552317
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708.24552317
129. Lombardi G De Salvo GL Brandes AA Eoli M Rudà R Faedi M Lolli I Pace A Daniele B Pasqualetti F Regorafenib compared with lomustine in patients with relapsed glioblas toma (REGOMA): a multicentre, open-label, randomised, controlled, phas e 2 trial Lancet Oncol 2019 20 110 9 10.1016/S1470-2045(18)30675-2 30522967
Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, et al. Regorafenib compared with lomustine in patients with relapsed glioblas toma (REGOMA): a multicentre, open-label, randomised, controlled, phas e 2 trial. Lancet Oncol. 2019;20:110–9.30522967
130. Reardon DA Brandes AA Omuro A Mulholland P Lim M Wick A Baehring J Ahluwalia MS Roth P Bähr O Effect of Nivolumab vs Bevacizumab in patients with recurrent Glioblas toma: the CheckMate 143 phase 3 Randomized Clinical Trial JAMA Oncol 2020 6 1003 10 10.1001/jamaoncol.2020.1024 32437507
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, et al. Effect of Nivolumab vs Bevacizumab in patients with recurrent Glioblas toma: the CheckMate 143 phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:1003–10.32437507
131. Reardon DA Kim TM Frenel J-S Simonelli M Lopez J Subramaniam DS Siu LL Wang H Krishnan S Stein K Massard C Treatment with pembrolizumab in programmed death ligand 1-positive rec urrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial Cancer 2021 127 1620 9 10.1002/cncr.33378 33496357
Reardon DA, Kim TM, Frenel J-S, Simonelli M, Lopez J, Subramaniam DS, Siu LL, Wang H, Krishnan S, Stein K, Massard C. Treatment with pembrolizumab in programmed death ligand 1-positive rec urrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial. Cancer. 2021;127:1620–9.33496357
132. Nayak L Standifer N Dietrich J Clarke JL Dunn GP Lim M Cloughesy T Gan HK Flagg E George E Circulating Immune Cell and Outcome Analysis from the phase II study o f PD-L1 blockade with Durvalumab for newly diagnosed and recurrent gli oblastoma Clin cancer Research: Official J Am Associa Tion Cancer Res 2022 28 2567 78 10.1158/1078-0432.CCR-21-4064
Nayak L, Standifer N, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy T, Gan HK, Flagg E, George E, et al. Circulating Immune Cell and Outcome Analysis from the phase II study o f PD-L1 blockade with Durvalumab for newly diagnosed and recurrent gli oblastoma. Clin cancer Research: Official J Am Associa Tion Cancer Res. 2022;28:2567–78.
133. Cloughesy TF Mochizuki AY Orpilla JR Hugo W Lee AH Davidson TB Wang AC Ellingson BM Rytlewski JA Sanders CM Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with i ntratumoral and systemic immune responses in recurrent glioblastoma Nat Med 2019 25 477 86 10.1038/s41591-018-0337-7 30742122
Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with i ntratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25:477–86.30742122
134. Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz, de Cerio A, Tejada S et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in re sectable glioblastoma. Nature medicine 2019, 25:470–476.
135. Nassiri F Patil V Yefet LS Singh O Liu J Dang RMA Yamaguchi TN Daras M Cloughesy TF Colman H Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent gliobla stoma: a phase 1/2 trial Nat Med 2023 29 1370 8 10.1038/s41591-023-02347-y 37188783
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent gliobla stoma: a phase 1/2 trial. Nat Med. 2023;29:1370–8.37188783
136. Duerinck J Schwarze JK Awada G Tijtgat J Vaeyens F Bertels C Geens W Klein S Seynaeve L Cras L Intracerebral administration of CTLA-4 and PD-1 immune checkpoint bloc king monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial J Immunother Cancer 2021 9 e002296 10.1136/jitc-2020-002296 34168003
Duerinck J, Schwarze JK, Awada G, Tijtgat J, Vaeyens F, Bertels C, Geens W, Klein S, Seynaeve L, Cras L, et al. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint bloc king monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. J Immunother Cancer. 2021;9:e002296.34168003
137. Dominguez C, McCampbell KK, David JM, Palena C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight 2017, 2.
138. Bilusic M Heery CR Collins JM Donahue RN Palena C Madan RA Karzai F Marté JL Strauss J Gatti-Mays ME Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors J Immunother Cancer 2019 7 240 10.1186/s40425-019-0706-x 31488216
Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, Madan RA, Karzai F, Marté JL, Strauss J, Gatti-Mays ME, et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019;7:240.31488216
139. Rennard SI Dale DC Donohue JF Kanniess F Magnussen H Sutherland ER Watz H Lu S Stryszak P Rosenberg E Staudinger H CXCR2 antagonist MK-7123. A phase 2 proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease Am J Respir Crit Care Med 2015 191 1001 11 10.1164/rccm.201405-0992OC 25695403
Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, Watz H, Lu S, Stryszak P, Rosenberg E, Staudinger H. CXCR2 antagonist MK-7123. A phase 2 proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;191:1001–11.25695403
140. Schott AF Goldstein LJ Cristofanilli M Ruffini PA McCanna S Reuben JM Perez RP Kato G Wicha M Phase ib pilot study to Evaluate Reparixin in Combination with Weekly Paclitaxel in patients with HER-2-Negative metastatic breast Cancer Clin Cancer Res 2017 23 5358 65 10.1158/1078-0432.CCR-16-2748 28539464
Schott AF, Goldstein LJ, Cristofanilli M, Ruffini PA, McCanna S, Reuben JM, Perez RP, Kato G, Wicha M. Phase ib pilot study to Evaluate Reparixin in Combination with Weekly Paclitaxel in patients with HER-2-Negative metastatic breast Cancer. Clin Cancer Res. 2017;23:5358–65.28539464
141. Acker G Zollfrank J Jelgersma C Nieminen-Kelhä M Kremenetskaia I Mueller S Ghori A Vajkoczy P Brandenburg S The CXCR2/CXCL2 signalling pathway - an alternative therapeutic approach in high-grade glioma Eur J Cancer 2020 126 106 15 10.1016/j.ejca.2019.12.005 31927212
Acker G, Zollfrank J, Jelgersma C, Nieminen-Kelhä M, Kremenetskaia I, Mueller S, Ghori A, Vajkoczy P, Brandenburg S. The CXCR2/CXCL2 signalling pathway - an alternative therapeutic approach in high-grade glioma. Eur J Cancer. 2020;126:106–15.31927212
142. Herbertz S Sawyer JS Stauber AJ Gueorguieva I Driscoll KE Estrem ST Cleverly AL Desaiah D Guba SC Benhadji KA Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Drug Des Devel Ther 2015 9 4479 99 26309397
Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015;9:4479–99.26309397
143. Wick A Desjardins A Suarez C Forsyth P Gueorguieva I Burkholder T Cleverly AL Estrem ST Wang S Lahn MM Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma Invest New Drugs 2020 38 1570 9 10.1007/s10637-020-00910-9 32140889
Wick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T, Cleverly AL, Estrem ST, Wang S, Lahn MM, et al. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Invest New Drugs. 2020;38:1570–9.32140889
144. Sawyer JS Anderson BD Beight DW Campbell RM Jones ML Herron DK Lampe JW McCowan JR McMillen WT Mort N Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain J Med Chem 2003 46 3953 6 10.1021/jm0205705 12954047
Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem. 2003;46:3953–6.12954047
145. Brandes AA Carpentier AF Kesari S Sepulveda-Sanchez JM Wheeler HR Chinot O Cher L Steinbach JP Capper D Specenier P A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma Neuro Oncol 2016 18 1146 56 10.1093/neuonc/now009 26902851
Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, et al. A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol. 2016;18:1146–56.26902851
146. Abdelfattah N Kumar P Wang C Leu JS Flynn WF Gao R Baskin DS Pichumani K Ijare OB Wood SL Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target Nat Commun 2022 13 767 10.1038/s41467-022-28372-y 35140215
Abdelfattah N, Kumar P, Wang C, Leu JS, Flynn WF, Gao R, Baskin DS, Pichumani K, Ijare OB, Wood SL, et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun. 2022;13:767.35140215
147. Feng YH Lim SW Lin HY Wang SA Hsu SP Kao TJ Ko CY Hsu TI Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression J Steroid Biochem Mol Biol 2022 219 106067 10.1016/j.jsbmb.2022.106067 35114375
Feng YH, Lim SW, Lin HY, Wang SA, Hsu SP, Kao TJ, Ko CY, Hsu TI. Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression. J Steroid Biochem Mol Biol. 2022;219:106067.35114375
148. Lu C Liu J Yao M Li L Li G Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells BMC Cancer 2020 20 261 10.1186/s12885-020-06768-7 32228516
Lu C, Liu J, Yao M, Li L, Li G. Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells. BMC Cancer. 2020;20:261.32228516
149. Zhang S Guo M Liu Q Liu J Cui Y Neutrophil extracellular traps induce a hypercoagulable state in glioma Immun Inflamm Dis 2021 9 1383 93 10.1002/iid3.488 34288521
Zhang S, Guo M, Liu Q, Liu J, Cui Y. Neutrophil extracellular traps induce a hypercoagulable state in glioma. Immun Inflamm Dis. 2021;9:1383–93.34288521
150. Shafqat A Noor Eddin A Adi G Al-Rimawi M Abdul Rab S Abu-Shaar M Adi K Alkattan K Yaqinuddin A Neutrophil extracellular traps in central nervous system pathologies: a mini review Front Med (Lausanne) 2023 10 1083242 10.3389/fmed.2023.1083242 36873885
Shafqat A, Noor Eddin A, Adi G, Al-Rimawi M, Abdul Rab S, Abu-Shaar M, Adi K, Alkattan K, Yaqinuddin A. Neutrophil extracellular traps in central nervous system pathologies: a mini review. Front Med (Lausanne). 2023;10:1083242.36873885
151. Manda-Handzlik A, Demkow U. The Brain Entangled: The Contribution of Neutrophil Extracellular Traps to the Diseases of the Central Nervous System. Cells 2019, 8.
152. Ocana A Nieto-Jimenez C Pandiella A Templeton AJ Neutrophils in cancer: prognostic role and therapeutic strategies Mol Cancer 2017 16 137 10.1186/s12943-017-0707-7 28810877
Ocana A, Nieto-Jimenez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017;16:137.28810877
153. Chu D Dong X Shi X Zhang C Wang Z Neutrophil-based drug Delivery systems Adv Mater 2018 30 e1706245 10.1002/adma.201706245 29577477
Chu D, Dong X, Shi X, Zhang C, Wang Z. Neutrophil-based drug Delivery systems. Adv Mater. 2018;30:e1706245.29577477
154. Wang J Tang W Yang M Yin Y Li H Hu F Tang L Ma X Zhang Y Wang Y Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy Biomaterials 2021 273 120784 10.1016/j.biomaterials.2021.120784 33848731
Wang J, Tang W, Yang M, Yin Y, Li H, Hu F, Tang L, Ma X, Zhang Y, Wang Y. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy. Biomaterials. 2021;273:120784.33848731
155. Zhang H, Li Z, Gao C, Fan X, Pang Y, Li T, Wu Z, Xie H, He Q. Dual-responsive biohybrid neutrobots for active target delivery. Sci Robot 2021, 6.
156. Chang Y Cai X Syahirah R Yao Y Xu Y Jin G Bhute VJ Torregrosa-Allen S Elzey BD Won YY CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy Nat Commun 2023 14 2266 10.1038/s41467-023-37872-4 37080958
Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, Bhute VJ, Torregrosa-Allen S, Elzey BD, Won YY, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. 2023;14:2266.37080958
157. Jayaraml MA Phillips JJ Role of the Microenvironment in Glioma Pathogenesis Annual Rev Pathology-Mechanisms Disease 2024 19 181 201 10.1146/annurev-pathmechdis-051122-110348
Jayaraml MA, Phillips JJ. Role of the Microenvironment in Glioma Pathogenesis. Annual Rev Pathology-Mechanisms Disease. 2024;19:181–201.
